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ABSTRACT

THE CLINICAL UTILITY OF MOLECULAR TYPING OF MULTIPLY-RESISTANT
PSEUDOMONAS AERUGINOSA IN CHILDREN WITH CYSTIC FIBROSIS
Ruth Ann Luna, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2010
Major Director: William Korzun, Ph.D.
Associate Professor, Department of Clinical Laboratory Sciences

Chronic infection with P. aeruginosa is expected in patients with cystic fibrosis
(CF), but the ability to delay, prevent, or better manage infection with multiply-resistant
P. aeruginosa (MRPA) can potentially increase quality of life and extend survival. The
Texas Children’s Hospital CF Care Center has identified an endemic MRPA strain
(dominant clone), and this study aimed to identify risk factors for acquisition of the clone
as well as determine differences in patient outcome associated with subsequent infection
with the clone.
The study included 71 patients with CF with documented MRPA infection.
Designation of patients as members of the dominant clone or a non-dominant clone group
was based on molecular typing by rep-PCR of MRPA isolates from respiratory cultures.

Patient data was collected from Port CF, the national patient registry of the CF
Foundation. Patient demographic information and clinical parameters prior to MRPA
infection were analyzed by logistic regression as potential risk factors. Differences in
patient outcome including change in BMI, change in FEV1, and hospitalization rate were
evaluated by MANOVA.
Recent hospitalization (< 90 days) was a statistically significant (p = 0.035) risk
factor for acquisition of the dominant clone. Patients hospitalized < 90 days prior to
MRPA diagnosis were four times more likely to be infected with the dominant clone, and
patients hospitalized 91-180 days prior were almost three times more likely. Increased
hospitalization rates were seen in the dominant clone group both pre- (11 more days/year)
and post-infection (14 more days/year) as compared to the non-dominant clone group.
Patients infected with the endemic strain exhibited poorer outcomes in terms of
nutritional status (3.73% decrease/year in BMI %ile) and lung function (3.7%
decrease/year in FEV1 %ile). Significant overlap in hospitalization episodes of patients
known to be infected with the dominant clone and patients subsequently infected with the
dominant clone was observed.
Recent hospitalization was a significant risk factor for infection with the dominant
MRPA clone, and following infection, patients infected with the endemic strain exhibited
declines in nutritional status and lung function and increased hospitalization rates. The
results suggest potentially increased virulence and transmissibility of the endemic MRPA
strain.

CHAPTER 1: INTRODUCTION

Multiply-resistant Pseudomonas aeruginosa (MRPA) is a common respiratory
pathogen found in patients with cystic fibrosis (CF) (Patient Registry 2008 Annual
Report, 2009). The bacteria routinely leads to chronic pulmonary infection, and the
infections have proven difficult to treat due to the organism’s resistance to many of the
commonly prescribed antibiotics (Falagas, Koletsi, & Bliziotis, 2006). The life
expectancy for patients with CF has dramatically increased in the past 20 years, but
persistent antibiotic-resistant infections continue to impact quality of life as well as
survival. The Cystic Fibrosis Care Center at Texas Children’s Hospital (TCH) in
Houston, Texas is a large CF Foundation-Accredited Care Center. However, while the
national average of multiply-resistant Pseudomonas aeruginosa infection in patients with
CF in 2006 was 16%, the average at the TCH CF Care Center was 30.1% (Patient
Registry 2006 Annual Report, 2008). This trend towards higher MRPA infection rates at
TCH remained present through the latest CF center-specific data for 2008 with a national
MRPA average of 17.9% and an average of 28% at TCH (Patient Registry 2008 Annual
Report, 2009). Prevention or delay of MRPA infections could significantly improve longterm patient prognosis and prolong the projected lifespan of patients with CF. Infection
with multiply-resistant P. aeruginosa, rather than a susceptible strain, has been associated
with greater risk of death or lung transplantation, and infection with specific P.
1
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aeruginosa epidemic strains has been implicated in increased patient morbidity (Al-Aloul
et al., 2004; Edenborough et al., 2004; Lechtzin et al., 2006; Nixon et al., 2001; O'Carroll
et al., 2004). Identification of risk factors for acquisition of a specific MRPA clone or
information regarding projected outcomes for patients infected with a specific MRPA
clone would be valuable tools for clinicians and infection control practitioners.
The Cystic Fibrosis Foundation Consensus Conference on Infection Control has
provided specific infection control guidelines in the hopes of reducing the number of
patients infected with MRPA in each of the CF clinics in the United States (Saiman &
Siegel, 2003). Various scenarios including social contact during hospitalization and
proper sterilization and decontamination during routine visits and procedures were
addressed. These infection control procedures are meant to decrease the possibility of
patient-to-patient transmission of MRPA and common source acquisition of MRPA.
Numerous investigators have employed strain typing technology to determine
whether the Pseudomonas aeruginosa strains infecting patients with CF in one treatment
center were genetically, or clonally, related (D. Armstrong et al., 2003; Jones et al., 2001;
Nixon et al., 2001; Scott & Pitt, 2004). Molecular typing allows for the identification of
different strains of a particular bacterial species. While all of the strains tested are the
same species (ex., Pseudomonas aeruginosa), subtle differences in the bacterial genomes
allow differentiation between strains that are unrelated and those that may have
originated from a common source. Clonally related strains will create a cluster, a group of
highly similar molecular fingerprinting patterns, when analyzed by molecular methods.
Various molecular methods that employ the polymerase chain reaction (PCR) including
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pulsed-field gel electrophoresis (PFGE), random amplification of polymorphic DNA
(RAPD) PCR, repetitive element PCR (rep-PCR), as well as other technologies have been
utilized for identification of related Pseudomonas aeruginosa strains. While some studies
did not yield evidence of clustering of Pseudomonas aeruginosa strains in patients with
CF (Agarwal, Kapil, Kabra, Das, & Dwivedi, 2005; da Silva Filho, Levi, Bento,
Rodrigues, & da Silvo Ramos, 2001; Silbert, Barth, & Sader, 2001; Spencker et al., 2000;
Tubbs et al., 2001), the majority of studies have discovered related strains of
Pseudomonas aeruginosa in their CF patient population (Edenborough et al., 2004;
Kersulyte, Struelens, Deplano, & Berg, 1995; O'Carroll et al., 2004; Scott & Pitt, 2004;
Syrmis et al., 2004). Several studies employing molecular typing of Pseudomonas
aeruginosa strains in their CF population not only found significant clustering but also
suggested that patients infected with the epidemic strain were more adversely affected
and required more treatment than patients infected with unique strains (Al-Aloul et al.,
2004; Edenborough et al., 2004; Nixon et al., 2001; O'Carroll et al., 2004).
Patients with CF infected with multiply-resistant Pseudomonas aeruginosa will
likely suffer worse outcomes than those with susceptible Pseudomonas aeruginosa
isolates. Patients infected with MRPA exhibit more rapid decline in routine pulmonary
function tests such as FEV1, the forced expiratory volume in one second (Lambiase et al.,
2006). One study reported that patients with CF infected with MRPA were 14 times more
likely to die or require a lung transplant than patients infected with Pseudomonas
aeruginosa that was not multi-drug resistant (Lechtzin et al., 2006).
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Research has been conducted comparing CF patient outcomes with MRPA versus
susceptible Pseudomonas aeruginosa and to determine relatedness of Pseudomonas
aeruginosa strains in patients with CF. However, to date, no study has been performed
that specifically analyzes CF patient-related variables and patient outcomes as they relate
to the clustered MRPA strains. If significant relationships were found between CF
patient-related variables and the acquisition of a specific MRPA strain, then preventative
measures could possibly stop or suppress the transmission of MRPA. Moreover, if
significant relationships were found between CF patient outcomes and a specific MRPA
strain, then treatment plans could be tailored based on the prognosis for that specific
MRPA strain.
Purpose Statement
The purpose of this study is twofold: to determine if there is a relationship
between CF patient-related variables and infection with a specific MRPA strain; and to
determine if there is a relationship between infection with a specific MRPA strain and CF
patient outcomes.
Research Questions
Is infection with the dominant MRPA clone related to patient-related variables prior to
MRPA infection?
Hypothesis: Certain CF patient-related variables are significantly related to infection with
the dominant MRPA clone. The CF patient-related variables to be studied included the
following: age at time of CF diagnosis, age at time of MRPA infection diagnosis, body
mass index (BMI), forced expiratory volume in one second (FEV1), days from last
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hospitalization to MRPA diagnosis, CFTR genotype, mother’s educational level, gender,
days from last clinic visit to MRPA diagnosis, tobramycin use, and respiratory culture
results. In addition to evaluating the entire group of patient-related variables, smaller
groups of variables related to patient demographics and clinical parameters at the time of
MRPA infection (including subsets related to chronology and disease state) were
analyzed.
Is CF patient outcome related to infection with the dominant MRPA clone?
Hypothesis: Patient outcomes such as death, change in FEV1, change in BMI, and
hospitalization rate are related to infection with the dominant MRPA clone.
Significance of the Study
The morbidity associated with MRPA infections in patients with CF is well
documented, but not all patients suffer the same decline in quality of life. While studies
have shown significant differences in patient outcomes with MRPA strains versus
antibiotic susceptible Pseudomonas aeruginosa isolates (Al-Aloul et al., 2004; Lambiase
et al., 2006; Lechtzin et al., 2006; Nixon et al., 2001), no research has been performed to
determine if there are significant differences in patient outcomes within the patient
population infected with MRPA.
If a significant relationship was discovered between CF patient-related variables
prior to MRPA infection and the subsequent MRPA strain, then clinicians may be able to
develop strategies to prevent transmission and new infections. If prevention is not
possible, then improved management or treatment plans may be implemented for patients
identified at risk for MRPA infection. If no significant relationship was discovered
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between CF patient-related variables and infection with a specific MRPA strain, then the
study would suggest that monitoring these characteristics prior to MRPA infection is not
necessary and that these characteristics should not be a focal point for infection control
guidelines and practices. If a significant relationship was discovered between a specific
MRPA strain and CF patient outcomes, then clinicians could tailor their treatment efforts
based on disease severity associated with that particular MRPA strain. More aggressive
and customized treatment or management plans could be implemented. If no significant
relationship exists between the MRPA strain and CF patient outcomes, then the study
would suggest that molecular typing data is not useful in prospective patient care.
Delimitations
The study included only pediatric patients with cystic fibrosis who were treated at
the CF Care Center of Texas Children’s Hospital. Patients in the sample population
included only those children who did not have a MRPA infection at the time of their first
visit to the hospital.
Assumptions
The following assumptions were made while conducting this study:
1) All patient-related variables and outcome data were correctly entered into Port
CF (version 1), the electronic national repository for CF patient data.
2) Measurement of patient data, such as lung function and weight, was accurate
and precise.
3) All MRPA infections were correctly diagnosed from respiratory cultures.
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4) All rep-PCR molecular fingerprinting profiles were sufficient to discriminate
between clonal groups.
5) All MRPA isolates from patients with cystic fibrosis who are eligible for the
study were sent to the Molecular Microbiology laboratory for DNA typing.
Definition of Terms
Multiply-resistant Pseudomonas aeruginosa (MRPA). A strain of Pseudomonas
aeruginosa that is resistant to at least two different classes of commonly used antibiotics.
The Cystic Fibrosis Foundation defines MRPA isolates as being resistant to all antibiotics
in at least two of three of the following antibiotic groups: aminoglycosides,
fluoroquinolones, and beta-lactams.
Cluster or clonal group. A group of bacterial isolates that yield highly similar molecular
fingerprinting patterns. By molecular typing, these isolates belong to one group that
represents a single clone. The terms bacterial clone and strain will be used
interchangeably in this study.
Organization of the Study
The study is presented in five chapters followed by a bibliography. Chapter Two
provides a review of the literature concerning cystic fibrosis, MRPA infections,
molecular typing techniques, and the clinical application of molecular typing. Chapter
Three describes the ex post facto research design and methodology of the study including
selection of the appropriate patient-related and patient outcome variables, details of the
molecular techniques utilized, and explanation of statistical analyses. Chapter Four
presents the results of the study. Chapter 5 concludes with a discussion of the data
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including a summary of the work and recommendations regarding how the information
could be used in future studies and current medical practice.

CHAPTER 2: LITERATURE REVIEW

The following chapter will present the background necessary for a discussion of
the application of molecular typing for multiply-resistant Pseudomonas aeruginosa in
patients with cystic fibrosis. General information regarding the disease of cystic fibrosis
such as underlying genetics, diagnostic testing, symptoms, and treatment strategies will
be provided. Commonly used patient outcome predictors for cystic fibrosis will also be
presented. Infection control as it relates to P. aeruginosa and cystic fibrosis will be
discussed as well as utilization of molecular typing technologies for epidemiology studies
in this special patient population. Finally, supporting information for the variables
employed in this study will be presented including potential risk factors for acquisition of
MRPA and patient outcome indicators.
Cystic Fibrosis
Cystic fibrosis (CF) is an autosomal recessive disease that affects 1 in 3,500
children born in the United States (Patient Registry 2008 Annual Report, 2009).
Approximately 30,000 people live with a diagnosis of cystic fibrosis in the United States,
and while most patients are Caucasian, CF can affect individuals of all ethnicities. CF
occurs at a rate of 1 in 9,500 Hispanics and less than 1 in 50,000 in native Africans and
Asians. African Americans and Asian Americans have a higher incidence of 1 in 15,300
and 1 in 32,100 respectively (National Institutes of Health, 1997). CF is an autosomal
9
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recessive disease, and an individual must have two mutations of the CFTR gene (one on
each copy of chromosome 7) in order to be clinically affected with cystic fibrosis;
therefore, individuals identified as CF carriers are more common. Carrier rates for cystic
fibrosis are 1 in 29 for the Ashkenazi Jewish and European Caucasian populations, 1 in
46 for Hispanic Americans, 1 in 65 for African Americans, and 1 in 90 for Asian
Americans (Grody et al., 2001).
Dr. Dorothy Andersen first described CF as a separate disease in a case report in
1938 (Andersen, 1958). However, even as early as the Middle Ages, a childhood
disorder characterized by salty sweat and early death was described (Rudolph &
Rudolph, 2002). In 1953, physicians discovered that patients with cystic fibrosis
produced sodium and chloride concentrations in sweat that were 2-4 times greater than
values found in patients with a variety of other conditions (Di Sant'Agnese, Darling,
Perera, & Shea, 1953). The high concentrations of sodium and chloride in the sweat of
patients with CF was subsequently found to be due to poor reabsorption of sodium
chloride in the sweat duct (Quinton, 1983).
The cystic fibrosis transmembrane conductance regulator (CFTR) gene was first
characterized in 1989. The CFTR gene is located on the long arm of chromosome 7
(7q.31.2) and spans approximately 250,000 base pairs (Rommens et al., 1989). Defective
CFTR alleles contain a variety of mutations (B. Kerem et al., 1989). DeltaF508, by far
the most common mutation present in 70% of CF patients, was discovered during the
initial sequencing of the gene (Riordan et al., 1989). The deltaF508 mutation is a three-
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nucleotide deletion in the tenth exon of the CFTR gene that causes the loss of a single
phenylalanine residue within a protein of 1480 amino acids.
Experiments correcting defective chloride transport led to the discovery that
mutations in the CFTR gene were responsible for the phenotypic defect (Rich et al.,
1990). The CFTR gene undergoes transcription into mRNA and then translation into
protein in the endoplasmic reticulum. The CFTR protein is then glycosylated in the Golgi
apparatus and folded into the proper conformation that allows it to assume the
appropriate place in the apical membranes of epithelial cells (Rudolph & Rudolph, 2002).
The CFTR protein functions as a chloride channel, which is regulated by cyclic AMP,
and the interaction of two CFTR nucleotide binding domains is crucial to the protein’s
viability (Anderson et al., 1991). The CFTR protein not only conducts chloride, but it
also regulates other chloride secretory pathways. The various mutations in the CFTR
gene affect the protein’s function in different manners causing varied effects on the
protein’s ability to both conduct and regulate conduction of chloride ions (Devidas &
Guggino, 1997). For instance, the phenylalanine deletion at position F508 results in
improper folding of the nucleotide binding domains of CFTR. The altered protein is
retained within the endoplasmic reticulum and is targeted for degradation (Ko &
Pedersen, 1997). However, research has shown that it is possible for a mutant protein to
assume a functional conformation when conditions are altered appropriately in vitro (Qu,
Strickland, & Thomas, 1997).
As of October 2008, 1,604 mutations were implicated in cystic fibrosis, and the
most common types of defects were missense (42%) and frameshift (16%) mutations
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(www.genet.sickkids.on.ca/cftr/app). As mentioned previously, the single most common
mutation found on 70% of CF chromosomes is deltaF508, and that mutation has a high
degree of association with increased symptoms leading to greater disease severity
(Riordan et al., 1989). Researchers have grouped the various mutations into classes that
describe how the mutations affect the presence of the CFTR protein in the apical
membranes of epithelial cells, and these classes (Table 1) are also generally associated
with disease severity (Pilewski & Frizzell, 1999; Zielenski, 2000).
Table 1.
CFTR Mutation Classes and Their Effect on the CFTR Protein and Disease Severity
Mutation class
Class I
Class II
Class III
Class IV
Class V
Class VI

Effect on CFTR protein
Defective protein synthesis due to
translation failure
Premature degradation of CFTR by
proteases in the endoplasmic reticulum
CFTR protein is nonfunctional
Normal amount of CFTR protein with
residual function
Reduced amount of functional CFTR
present at the cell membrane
Functional but unstable version of CFTR

Disease phenotype
Severe
Severe
Severe
Mild pancreatic
insufficiency
Mild
Severe

CFTR genotypes, which include two copies of a defective CFTR gene, can
provide physicians with valuable information on expected disease severity such as
exocrine pancreatic function (Kristidis et al., 1992). Genotype alone does not predict
severity of pulmonary disease among patients with cystic fibrosis due to the variability
within groups of patients with the same genotype (The Cystic Fibrosis GenotypePhenotype Consortium, 1993). However, it is still believed that heritability factors
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beyond the CF genotype may play a significant role in pulmonary disease severity based
on comparisons of sibling data (Vanscoy et al., 2007).
Cystic fibrosis is generally characterized by copious mucus secretions present on
mucosal surfaces, especially the gastrointestinal and respiratory tracts, leading to the
classic CF phenotype of chronic obstructive lung disease, exocrine pancreatic
insufficiency, and elevated sweat chloride concentrations (Zielenski, 2000). In addition,
infertility is extremely common in patients with CF due to thick cervical mucus in
women and congenital absence of the vas deferens leading to obstructive azoospermia in
men (Jequier, Ansell, & Bullimore, 1985). In 10-20% of patients with CF, thickened
intestinal mucus and pancreatic insufficiency can result in bowel obstruction at birth,
termed meconium ileus. Distal intestinal obstruction syndrome occurs later in life for 2025% of patients with CF (Rudolph & Rudolph, 2002). Pulmonary disease is worsened by
the bacterial colonization of the lungs. Inhaled bacteria are trapped and cleared more
slowly due to the reduced water content in the mucociliary secretions (Davis, 2006).
Additional complications for patients with cystic fibrosis include CF-related diabetes,
bone disease, liver disease, and nasal polyps that often require surgery (Patient Registry
2006 Annual Report, 2008).
Patients with cystic fibrosis have seen major improvements in life expectancy
during the past 40 years. In 1962, a patient diagnosed with CF was only expected to live
an average of 10 years (www.cff.org). In the most recent Patient Registry Annual Report,
the Cystic Fibrosis Foundation stated that the median survival age for a patient with CF
was 37.4 years of age in 2008 (Patient Registry 2008 Annual Report, 2009). Interestingly,
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a study by Kulich in 2003 found that the greatest improvement in life expectancy was
seen for patients between 2 and 15 years of age, and while both genders experienced
extended life expectancies, female patients continued to have poorer survival rates than
male patients in the category of 2 to 20 years of age (Kulich, Rosenfeld, Goss, &
Wilmott, 2003).
Diagnostic Testing for Cystic Fibrosis
In the United States, the median age of diagnosis for patients with cystic fibrosis
is 5.3 months. Patients who have undergone newborn screening are diagnosed at a
median age of 15 days, patients with meconium ileus are diagnosed at a median age of 6
days, and patients with other symptoms are diagnosed at a median age of 14.5 months.
Notably, patients diagnosed after the onset of symptoms as opposed to newborn
screening results are at a greater than 2-fold risk of medical complications before
diagnosis (Accurso, Sontag, & Wagener, 2005).
Newborn screening is generally performed by a biochemical test for
immunoreactive trypsinogen in plasma collected at birth, and the initial screen is
followed by repeat biochemical testing and CF mutation detection (Davidson, Wong,
Kirby, & Applegarth, 1984). Localities in the United Kingdom have been performing
newborn screening for CF since the mid-1980s, and Australia and France both have
comprehensive national neonatal screening programs (Brice, Jarrett, & Mugford, 2007).
The United States has recently mandated nation-wide newborn screening for CF, and in
2010, all 50 states now offer newborn screening for cystic fibrosis (www.cff.org).
Newborn screening enables much earlier diagnosis of cystic fibrosis when compared to
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symptomatic presentation. This early diagnosis occurs approximately one year earlier in
life and allows for earlier nutritional treatments leading to improved growth, improved
cognitive development, and a reduction in the number of days hospitalized (Grosse et al.,
2004).
Beyond newborn screening, several other diagnostic approaches for cystic fibrosis
include the sweat test, measuring nasal potential difference, and mutational studies of the
CFTR gene. Various testing algorithms are based on initial clinical indications and
require a combination of methods for the final diagnosis of cystic fibrosis (De Boeck et
al., 2006).
The gold standard for the diagnosis of cystic fibrosis remains the sweat test.
Sweating is induced by pilocarpine iontophoresis in which a colorless, odorless
compound (pilocarpine) is placed on the skin, and a small electric current is applied. The
sweat is collected onto preweighed gauze or filter paper that is then reweighed, and the
chloride is eluted into an exact volume of deionized water (L. E. Gibson & Cooke, 1959).
A volume of 50-100 µL of sweat is adequate for the sweat chloride concentration to be
measured. Macroduct collection systems are also available and allow the sweat to be
collected directly from the skin into a capillary tube, following the pilocarpine
iontophoresis procedure (Hammond, Turcios, & Gibson, 1994). Sweat chloride
concentrations less than 40 mmol/L essentially rule out CF, concentrations between 4060 mmol/L are considered borderline, and concentrations greater than 60 mmol/L are
considered consistent with a diagnosis of CF (De Boeck et al., 2006). Prior research has
found that 98% of patients with cystic fibrosis have sweat chloride concentrations greater
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than 60 mmol/L (Koch & Hoiby, 2000). Another study found that 23% of patients with
intermediate sweat chloride levels (30-60 mmol/L) contained known mutations in both
CFTR alleles (Lebecque et al., 2002).
Another tool for the diagnosis of cystic fibrosis is measurement of nasal potential
difference. The characteristically increased chloride secretion and elevated sodium
reabsorption causes abnormal nasal potential differences across apical cell membranes in
patients with cystic fibrosis, compared with healthy individuals and patients with a
variety of other disorders (Knowles, Gatzy, & Boucher, 1981). Nasal potential difference
is generally used as an additional method of confirmation when sweat tests and mutation
studies are inconclusive.
Mutation studies for cystic fibrosis are important in the diagnosis of the disease,
but genetic tests are also used for prenatal screening of either the parents or the fetus in
utero. In 2001, a joint effort between the American College of Medical Genetics, the
American College of Obstetricians and Gynecologists, and the National Institutes of
Health produced recommendations for population-based cystic fibrosis carrier screening
(Grody et al., 2001). The recommendations stated that testing should be offered to all
non-Jewish Caucasians and Ashkenazi Jews as well as all other ethnic groups. The
standard screening panel detailed in the document included 25 mutations, all with an
allele frequency greater than 0.1% in the US population. In 2004, the recommended panel
was revised slightly, removing two mutations (Watson et al., 2004). The first mutation
removed, 1078delT, was found to be present in only 0.03% of the US population, and the
second mutation removed, I148T, was determined incapable of causing classical CF as a
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single defect. The updated recommendations also noted six additional mutations not
listed in the panel that were found at an allele frequency of 0.1-0.17%, but additions to
the revised 23 mutation panel for cystic fibrosis screening were not recommended.
Various molecular testing platforms for cystic fibrosis are available, and the vast
majority of the assays employ multiplex PCR targeting of the CFTR gene. All assays
target a minimum of 23 recommended mutations, but several panels include additional
mutations to increase detection in ethnic groups other than Caucasians. Detection
technologies include but are not limited to oligonucleotide ligation assays, line probe
assays, liquid bead arrays, and microarrays (Johnson, Yoshitomi, & Richards, 2007;
Krafft & Lichy, 2005). Additionally, laboratories offer complete sequencing of the CFTR
gene and may detect up to 98% of mutations for all ethnic groups
(www.genzymegenetics.com).
Treatment of Cystic Fibrosis
The Cystic Fibrosis Foundation recommends that patients visit their physician at
least four times per year in clinics specializing in treatment of CF patients. In addition,
pulmonary function tests should be performed two times or more per year. At least one
respiratory culture should be collected per year (although many clinics collect respiratory
culture specimens at each visit), and creatinine levels, glucose levels (if older than 14
years of age), and quantitative liver enzymes should be tested at least once per year
(Patient Registry 2008 Annual Report, 2009). Research has shown that patients with
cystic fibrosis attending dedicated CF centers had better clinical outcomes such as higher
body mass index and better lung function than those receiving care at other types of
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centers (Mahadeva et al., 1998). In caring for patients with CF, home-based medications
account for the greatest proportion (47%) of the total cost of care (Baumann, Stocklossa,
Greiner, von der Schulenburg, & von der Hardt, 2003). Healthcare costs rise with age,
and chronic infection with Pseudomonas aeruginosa, which will be discussed in greater
detail later, is associated with healthcare costs three times higher than that of uninfected
patients with CF.
Malnutrition is common in patients with cystic fibrosis, primarily due to chronic
pancreatic insufficiency (Bines, Truby, Armstrong, Phelan, & Grimwood, 2002). Nearly
all patients with CF require pancreatic enzyme supplements with meals to prevent
nutritional deficiencies (Koch & Hoiby, 2000). Supplementation of fat-soluble vitamins
A, D, E, and K is also recommended due to fat malabsorption (Davis, 2006). Nutritional
supplements such as additional vitamins, pancreatic enzymes, and calorie-dense dietary
additions are crucial to the treatment of patients with CF due to the documented
relationship between nutritional status and pulmonary function (Milla, 2007).
In 2008, 3.8% of patients with cystic fibrosis 6-12 years of age were on ibuprofen
therapy (Patient Registry 2008 Annual Report, 2009). Konstan, et al., reported that
children with mild lung disease treated with ibuprofen for an average of four years had a
29% less decline in lung function than those not treated with ibuprofen (Konstan,
Schluchter, Xue, & Davis, 2007). The addition of anti-inflammatory therapy to a
thorough treatment program may decrease morbidity and improve quality of life for
young patients with mild lung disease (Chmiel & Konstan, 2007).
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Respiratory therapy for patients with cystic fibrosis includes airway clearance
techniques and aerosolized medication delivery. Most patients use a combination of
airway clearance techniques including exercise, positive expiratory pressure, coughing,
and active cycle breathing exercises among others. While there is acceptable adherence to
airway clearance schedules by patients with CF, the most common reasons for nonadherence were being too busy and too tired (White, Stiller, & Haensel, 2007). The
cleaning of nebulizers and airway clearance devices is especially important and is
generally performed by either boiling, soaking in bleach/rubbing alcohol/hydrogen
peroxide, microwaving, or placing in the dishwasher (Reychler et al., 2005).
Hypertonic saline and Pulmozyme® are important inhaled treatments for patients
with cystic fibrosis. By restoring hydration to the airway epithelium, inhaled hypertonic
saline allows increased airway clearance and improves lung function (Elkins et al., 2006).
Pulmozyme®, or dornase alfa, is a recombinant human DNase that thins mucus by
hydrolyzing the DNA released from neutrophils (Shak, Capon, Hellmiss, Marsters, &
Baker, 1990). The aerosolized drug is used by 76.1% of patients with cystic fibrosis who
are older than six years of age and have mild to severe lung disease (Patient Registry
2008 Annual Report, 2009). Pulmozyme® was the first drug developed specifically for
cystic fibrosis, and its use is associated with a slower rate of decline in lung function
(Konstan, 2008).
There are varying antibiotic treatment regimens including continuous treatment,
on-demand treatment, and early aggressive treatment (Koch & Hoiby, 2000). Continuous
treatment risks the development of antibiotic resistance, and on-demand treatment could
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possibly lead to under treatment. Antibiotic treatment in cystic fibrosis is commonly
directed specifically at infection with Pseudomonas aeruginosa. A multi-year study at a
Danish CF center evaluated an early anti-Pseudomonas aeruginosa treatment regimen.
Initial results showed that the treatment resulted in improved survival for their patients
(Frederiksen, Lanng, Koch, & Hoiby, 1996). Continued evaluation of the treatment at
their center found that those treated with high-dose colistin by inhalation and oral
ciprofloxacin showed the best results in delayed onset or prevention of chronic P.
aeruginosa infection (Frederiksen, Koch, & Hoiby, 1997). The treatment plan from the
Danish study also resulted in the maintenance of increased pulmonary function after
initiation of treatment. The groups credited cohort isolation based on P. aeruginosa
infection status for reducing the number of patients chronically infected with P.
aeruginosa (Frederiksen, Koch, & Hoiby, 1999).
The early and aggressive treatment protocol has been adopted and modified by
many cystic fibrosis centers. For instance, one center describes an increasingly aggressive
treatment protocol each time P. aeruginosa is isolated (Koch, 2002). The treatment plan
begins with three weeks of inhaled colistin upon the first isolation of P. aeruginosa. A
second positive P. aeruginosa culture justifies three more weeks of colistin with double
the usual dose. Treatment for a third positive culture supports doubling the dosage of
colistin for three months, and all treatment plans for repeated positive cultures also
include oral ciprofloxacin therapy.
With acute P. aeruginosa infections, early antibiotic therapy can eliminate P.
aeruginosa for a short period of time (approximately 18 months by one study) and thus
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delay lung function decline (Taccetti, Campana, Festini, Mascherini, & Doring, 2005). In
contrast, chronic infections with P. aeruginosa are difficult to eradicate (Doring et al.,
2000).
With continued advancements in antibiotics, azithromycin has become the drug of
choice for treating P. aeruginosa in patients with cystic fibrosis. In 2008, a total of 65.6%
of patients with cystic fibrosis who were older than six years of age, positive for P.
aeruginosa infection, had moderate to severe lung disease, and weighed more than 55
pounds were on azithromycin therapy (Patient Registry 2008 Annual Report, 2009).
Initial trials with azithromycin found that treatment reduced the rate of decline in lung
function, reduced the number of respiratory exacerbations, and improved nutritional
status and quality of life (Wolter et al., 2002). In 2003, the Cystic Fibrosis Foundation
recommended administration of azithromycin for patients with cystic fibrosis greater than
six years of age and chronically infected with P. aeruginosa (Saiman et al., 2003).
Interestingly, while azithromycin resulted in clinical improvement, a significant reduction
in bacterial density was not observed; and this phenomenon suggests that the
antimicrobial properties of azithromycin are the reason for the clinical response (Nguyen
et al., 2007). More recent studies also suggest that while improvements in pulmonary
function were seen in the first year of azithromycin treatment, pulmonary function
declined with longer courses of therapy (Tramper-Stranders, Wolfs, Fleer, Kimpen, &
van der Ent, 2007).
Inhaled forms of antibiotics have shown the most recent promise for the treatment
of bacterial infections in patients with cystic fibrosis. Tobramycin solution for inhalation
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(TOBI) was used by 67.4% of patients with cystic fibrosis in 2008 who were older than
six years of age, positive for P. aeruginosa, and had moderate to severe lung disease
(Patient Registry 2008 Annual Report, 2009). Although TOBI use is recommended for
patients with cystic fibrosis, concerns persist regarding the emergence of resistant
organisms with use of the drug (Hagerman, Knechtel, & Klepser, 2007). Cheer, et al.
reported a decline in the susceptibility of P. aeruginosa infections treated with TOBI, but
this reduced susceptibility did not cause adverse outcomes in the patients with CF (Cheer,
Waugh, & Noble, 2003). The most recently approved inhaled antibiotic is aztreonam,
which was FDA-approved in 2010. Aztreonam treatment has been combined with the
new eFlow electronic nebulizer delivery system that is capable of providing 1 mL of the
drug in two to three minutes (R. L. Gibson et al., 2006). This new treatment option
provides concentrations of aztreonam in the sputum of patients with CF that exceed the
concentrations necessary to inhibit bacterial growth of P. aeruginosa.
The selection of appropriate antibiotic treatment for patients with cystic fibrosis is
based on susceptibility patterns of the bacterial organisms (Doring et al., 2000). Recently,
concerns have surfaced that antibiotic combinations effective in vitro will not be as
effective in the lungs of patients with CF, especially in the presence of biofilms (Hill et
al., 2005). In addition, the selective stress of antibiotic treatment has been shown to
increase the rate of organisms that are resistant to multiple antibiotics (Alonso,
Campanario, & Martinez, 1999). The clinical significance of multiply-resistant P.
aeruginosa and Burkholderia cepacia is well established, but the significance of other
emerging multiply-resistant organisms such as methicillin-resistant Staphylococcus
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aureus (MRSA) and Stenotrophomonas maltophilia is still unknown (Waters & Ratjen,
2006).
Once all medication options have been exhausted and lung function reaches a
critical level, lung transplants must be considered for patients with cystic fibrosis. In
2008, a total of 157 patients with cystic fibrosis received lung transplants (Patient
Registry 2008 Annual Report, 2009). Referral criteria for lung transplants in patients with
cystic fibrosis includes severe decline in lung function, life-threatening pulmonary
complications, and increasing antibiotic resistance of bacterial pathogens infecting the
lungs (Yankaskas & Mallory, 1998). Infection with Burkholderia cenocepacia, panresistant Burkholderia multivorans, or pan-resistant Burkholderia vietnamiensis is
considered a contraindication to lung transplantation in patients with cystic fibrosis in the
United States due to poor survival rates post-surgery for patients infected with the
pathogen (Chaparro et al., 2001). However, pulmonary infection with multiply-resistant
Pseudomonas aeruginosa is not a contraindication for lung transplants in these patients
(Goldberg & Deykin, 2007).
Beyond the conventional treatment plans to alleviate symptoms and improve
quality of life, a cure for cystic fibrosis remains elusive. As in many genetic diseases,
gene therapy holds promise of providing a cure. Gene therapy targeted at cystic fibrosis
began with the correction of CFTR-dependent chloride transport by the use of nonviral
vectors in transgenic mice with cystic fibrosis (Hyde et al., 1993). Several routes of
administration of gene therapy have been evaluated since the initial studies. One study
utilized compacted DNA nanoparticles instilled into the nose. This approach to gene
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therapy did seem to provide partial to complete chloride transport correction in 8 of the
12 patients involved in the study (Konstan et al., 2004). Adeno-associated virus
transmitted via nasal installation or bronchoscopy has also been explored for delivery of
gene therapy; however, chloride transport correction was only observed in a few patients
(Flotte, Schwiebert, Zeitlin, Carter, & Guggino, 2005). Human clinical trials have
included recombinant adenovirus, recombinant adeno-associated virus, cationic
liposomes, and condensed naked DNA. So far, human clinical trials have not revealed a
single successful potential strategy for gene therapy in cystic fibrosis, but the possibility
of using embryonic or adult stem cells is also being explored (Sueblinvong, Suratt, &
Weiss, 2007).
Predictors of Outcome in Cystic Fibrosis
Several parameters have been used to predict patient outcomes in cystic fibrosis.
Interestingly, the presence of meconium ileus at birth was not found to be a significant
predictor of survival (Munck et al., 2006). However, genotypic determinations at birth
were found to be predictive of disease phenotype. The various mutation groups
mentioned earlier have been associated with different disease severities. Studies have
found significant differences in survival and median age of death between high-risk and
low-risk CF genotype classes (McKone, Goss, & Aitken, 2006). Even within genotypes
that include deltaF508, mortality rates and disease severity differ for patients that are
homozygous and heterozygous for the mutation (Johansen, Nir, Hoiby, Koch, &
Schwartz, 1991).
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Body-mass index (BMI) is a factor closely documented by physicians to monitor
patients with cystic fibrosis. The standards set by the Cystic Fibrosis Foundation state
that BMI is a percentile of weight and height compared to healthy children of the same
age and gender (Patient Registry 2008 Annual Report, 2009). Because BMI conveys
valuable information regarding nutritional status and overall patient health and prognosis,
several studies have identified BMI as an important predictor of survival in patients with
CF (Durie & Pencharz, 1992; Kraemer, Rudeberg, Hadorn, & Rossi, 1978). The CFF
states that patients with CF should exhibit growth consistent with age-matched
individuals who do not have the disease (Patient Registry 2008 Annual Report, 2009).
Another important measure in determining the health of a patient with cystic
fibrosis is forced expiratory volume (FEV1). FEV1 is “the volume of air that can be
forced out in one second after taking a deep breath” (Merriam-Webster's New World
Medical Dictionary, 2003). FEV1 can be expressed as volume in liters or as a percent
predicted based on healthy, non-smoking people of the same age and gender (Patient
Registry 2008 Annual Report, 2009). FEV1 has also been deemed a significant predictor
of survival, and one study reported that patients with a value less than 30% forced
expiratory volume in one second had a 50% chance of dying within two years (Corey,
Edwards, Levison, & Knowles, 1997; Kerem, Reisman, Corey, Canny, & Levison, 1992).
Pulmonary infection with bacterial pathogens is another significant factor in the
health and survival of patients with cystic fibrosis. Variants of Staphylococcus aureus
have been associated with more advanced lung disease (Besier et al., 2007). However,
Pseudomonas aeruginosa is the most significant respiratory pathogen in patients with CF,
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and infection with multiply-resistant P. aeruginosa is associated with a significant
decrease in FEV1 (Lambiase et al., 2006). Relative to demographic information, a
mother’s educational level has been identified as a potential risk factor for the acquisition
of P. aeruginosa (Kosorok et al., 1998; Watts, Seshadri, Sullivan, & McColley, 2009).
Interestingly, patients with a late diagnosis of cystic fibrosis (at 24 years of age or later)
were less likely to be infected with P. aeruginosa than those diagnosed at an earlier age
(before 15 years of age) (Rodman et al., 2005). Another study suggests that pulmonary
infection with P. aeruginosa or Burkholderia cepacia may have a greater effect on
survival than genotype (Courtney et al., 2007). When looking exclusively at P.
aeruginosa, patients infected with a multiply-resistant strain rather than a susceptible
strain were 14 times more likely to either die or need a lung transplant (Lechtzin et al.,
2006).
Infection Control in Cystic Fibrosis
A study in the cystic fibrosis centers of Germany found that physicians have
differing opinions on the risk of bacterial acquisition, specifically P. aeruginosa, from the
environment and suggested that strict precautions created a greater level of fear for the
patient and their family (Steinkamp & Ullrich, 2003). Cystic fibrosis centers in the
United States had a different view, and in 2003, the Cystic Fibrosis Foundation published
a consensus statement regarding infection control in cystic fibrosis (Saiman & Siegel,
2003). The document covered isolation procedures for patients with CF and also
recommended the use of molecular typing for surveillance of transmission of infections.
Consensus committee members made further recommendations in 2004 and noted the
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importance of monitoring infection control practices as well as tracking details on new
infections (Saiman & Siegel, 2004). The recommendations stated that patients with cystic
fibrosis should be instructed on containment of secretions and should maintain a distance
of at least three feet from other patients with CF regardless of respiratory infection status.
Cystic fibrosis centers were also instructed to standardize protocols for the cleaning of
equipment used in respiratory therapies and to educate patients and families on proper
care and disinfection of home use equipment. A significant proportion of home
nebulizers were contaminated with P. aeruginosa highlighting the importance of
infection control practices (Rosenfeld, Joy, Nguyen, Krzewinski, & Burns, 2001).
Isolation of hospitalized patients with cystic fibrosis infected with P. aeruginosa
is commonly accepted due to the many studies suggesting transmission between patients.
One review of the literature, found that 31 of 39 studies showed evidence of patient-topatient spread of P. aeruginosa in patients with cystic fibrosis (Vonberg & Gastmeier,
2005). Multiply-resistant strains of P. aeruginosa are assumed to be even more
transmissible, so segregation is critical for those patients (Davies, McShane, Davies, &
Bush, 2003). Multiple studies have suggested that molecular epidemiologic surveillance
is needed to determine if improved infection control practices limit the spread of P.
aeruginosa between patients with cystic fibrosis (D. Armstrong et al., 2003; O'Carroll et
al., 2004; Pitt, 2002; Ramsey, 2002).
Pseudomonas aeruginosa
Pseudomonas aeruginosa is a fastidious organism that prefers moist environments
and surfaces. When placed on filter paper or freeze dried, P. aeruginosa has a survival
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rate of 10-150 days. However when placed in water at 4-37°C, P. aeruginosa was found
to survive for more than 300 days (Emmanouilidou-Arseni & Koumentakou, 1964).
Because of this extended survival, P. aeruginosa is a significant factor in deviceassociated nosocomial infections involving urinary catheters, central venous catheters,
and ventilators (Pierce, 2005). It is believed that bacterial biofilms may coat these devices
and account for persistent contamination.
Beyond cystic fibrosis, P. aeruginosa is an important pathogen in other disease
states such as immunocompromised patients with cancer or HIV infection. P. aeruginosa
is a primary consideration for patients with leukemia and in neutropenic patients (Funada
& Matsuda, 1998). The frequency of P. aeruginosa infections in patients with solid
tumors has decreased but has remained constant for patients with acute leukemia
(Chatzinikolaou et al., 2000). In addition, hospitalized patients with HIV-1 infection are
susceptible to community-acquired and nosocomial bacterial pneumonia commonly
caused by P. aeruginosa (Afessa & Green, 2000).
Pseudomonas aeruginosa in Cystic Fibrosis
The Cystic Fibrosis Foundation Patient Registry Report noted that 52.5% of
patients with cystic fibrosis were infected with Pseudomonas aeruginosa in 2008 (Patient
Registry 2008 Annual Report, 2009). Earlier studies hoped to discover risk factors for the
acquisition of P. aeruginosa. The presence of meconium ileus at birth was once found to
be a significant risk factor, but advances in infection control and surgical treatment have
lessened this risk (E. Kerem et al., 1989). Clinic exposures and use of aerosol
medications and treatments have also been proven to increase the risk of acquisition of P.
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aeruginosa. Interestingly, the level of education of the patient’s mother was found to
decrease the risk of acquiring P. aeruginosa presumably due to relative abilities to clean
and handle respiratory therapy equipment (Kosorok et al., 1998).
Evidenced by whole genome analysis, P. aeruginosa genetically adapts to the
airways of patients with cystic fibrosis. Genetic properties differed greatly between the P.
aeruginosa strains that initiated the infection and the strains present late in P. aeruginosa
infections of cystic fibrosis airways (Smith et al., 2006). P. aeruginosa present in acute or
early infection stages have a non-mucoid appearance, are pan-sensitive to antibiotics, and
are present at low densities (Rosenfeld, Ramsey, & Gibson, 2003). Several studies have
shown that a window of opportunity may be present in which early intervention may
allow eradication of P. aeruginosa from upper and lower airways (Treggiari, Rosenfeld,
Retsch-Bogart, Gibson, & Ramsey, 2007). However, selective pressure has been shown
to promote the transformation of non-mucoid strains into mucoid phenotypes resulting in
chronic P. aeruginosa infections.
P. aeruginosa is observed as a biofilm in the sputum of patients with cystic
fibrosis (P. K. Singh et al., 2000). In P. aeruginosa infections of the airways of patients
with cystic fibrosis, the mucus is targeted rather than the epithelial cell surface
compartment (Worlitzsch et al., 2002). The mucoid morphology associated with chronic
infection is caused by the overproduction of extracellular polysaccharide alginate
(Driscoll, Brody, & Kollef, 2007). Alginate production facilitates the establishment of
microcolonies in biofilms, which protect pathogens from host defense mechanisms and
antimicrobial agents (Koch, 2002). Mucus clearance is part of a healthy respiratory
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system’s defense against infection, but patients with CF are unable to clear the thick
mucus characteristic of their disease leading to chronic lung infections (Worlitzsch et al.,
2002). Chronic infection with P. aeruginosa leads to decline in pulmonary function and
ultimately death in patients with cystic fibrosis (Lyczak, Cannon, & Pier, 2002).
The initial definition of chronic P. aeruginosa infection included the presence of
this pathogen in the sputa of the patients for a period of six months (Hoiby, 1974). In
2003, the Leeds criteria proposed revised definitions for the various stages of P.
aeruginosa infection (Lee, Brownlee, Conway, Denton, & Littlewood, 2003). “Chronic
infection” was defined as positive P. aeruginosa cultures during more than 50% of the
months when samples were obtained. “Intermittent infection” was defined as a positive P.
aeruginosa culture during 50% or less of the months when samples were obtained, and
“free of infection” was defined as no growth of P. aeruginosa in the previous 12 months
for patients with a prior history of Pseudomonas infection. More recent studies have
upheld the Leeds criteria and the definitions of patterns of P. aeruginosa infection
(Proesmans et al., 2006).
Clinical laboratories employ various techniques for the identification of P.
aeruginosa in respiratory samples of patients with cystic fibrosis. Serological tests can
detect specific antigens implicated in the diagnosis of chronic P. aeruginosa colonization,
but the test has failed to detect early colonization in young patients (Tramper-Stranders et
al., 2006). The identification method recommended by the Cystic Fibrosis Foundation
utilizes culture paired with agar diffusion assays for susceptibility testing of P.
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aeruginosa, but a recent study showed that only 52% of laboratories in the United States
use this methodology (Zhou, Garber, Desai, & Saiman, 2006).
In recent years, the identification of P. aeruginosa has been aided by new
molecular assays. The discovery of a nucleotide sequence present in all isolates of the
Liverpool epidemic strain led to a PCR assay capable of identifying that particular strain
in colonies or directly from sputum (Parsons et al., 2002). Another laboratory developed
an assay using temperature gradient gel electrophoresis paired with pyrosequencing to
identify P. aeruginosa in respiratory samples of patients with cystic fibrosis (Kolak,
Karpati, Monstein, & Jonasson, 2003). P. aeruginosa isolates as well as other atypical
nonfermenting gram-negative bacilli in patients with cystic fibrosis are known to have
atypical morphologies and metabolic properties, and these organisms often require
further testing for confirmation (Ferroni et al., 2002). One laboratory designed a PCR
assay to specifically identify difficult and non-typical P. aeruginosa in the sputa of
patients with cystic fibrosis (Spilker, Coenye, Vandamme, & LiPuma, 2004). At Texas
Children’s Hospital, a pyrosequencing assay was implemented to identify any organism
that proved difficult to definitively speciate by conventional microbiological methods.
Many of the organisms that were referred for this testing were found to be P. aeruginosa
isolates from patients with cystic fibrosis that did not perform as expected by culture and
both manual and automated biochemical testing methods (Luna et al., 2007).
Infection with P. aeruginosa has a profound effect on the lives of patients with
cystic fibrosis. On the emotional front, recent colonization with P. aeruginosa has been
associated with a lower quality of life (Goldbeck, Zerrer, & Schmitz, 2007). P.
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aeruginosa infections are also major predictors of morbidity and mortality. The clinical
outcomes of patients positive for P. aeruginosa respiratory infections are significantly
poorer due to lower lung capacity (FEV1), lower weight percentiles, and higher rates of
hospitalization. Most troublesome is the fact that the eight-year death risk is 2.6 times
higher for patients with P. aeruginosa isolated from respiratory cultures than for those
without P. aeruginosa in respiratory cultures (Emerson, Rosenfeld, McNamara, Ramsey,
& Gibson, 2002).
The largest complication with P. aeruginosa is the emergence of multiplyresistant strains, or strains that are resistant to multiple antibiotics. Various publications
attempt to define multiply-resistant P. aeruginosa, but the most widely accepted
definition is provided by the Cystic Fibrosis Foundation (CFF) and has been adopted by
CF centers throughout the United States (Falagas et al., 2006). According to the CFF, a P.
aeruginosa isolate must be resistant to all antibiotics in at least two of three groups
(aminoglycosides, fluoroquinolones, and beta-lactams) to be considered multiplyresistant. Studies have shown that treatment with certain antibiotics can affect the
emergence of antibiotic resistant strains of P. aeruginosa. One study found that
ceftazidime treatment yielded the lowest risk and imipenem yielded the highest risk of
emergence of antibiotic-resistant P. aeruginosa (Carmeli, Troillet, Eliopoulos, & Samore,
1999). Hypermutable strains also contribute to the development of antibiotic resistance,
and one study suggested that early and aggressive antibiotic treatment combined with
antioxidants could prevent mutation of the strains. The study claimed that strain typing by
pulsed field gel electrophoresis confirmed this hypothesis by showing patients had the
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same strain throughout the chronic lung infection phase (Ciofu, Riis, Pressler, Poulsen, &
Hoiby, 2005).
Molecular Typing Technology and Clinical Applications
While a variety of techniques for molecular typing exist, the goal of each
methodology is to determine if isolates of a specific species are clonally related. A clonal
relationship would suggest that they originated from the same bacterial cell and could
indicate a lateral or point source of transmission. The discriminatory power of a
technique describes the technique’s ability to differentiate unrelated isolates (A. Singh,
Goering, Simjee, Foley, & Zervos, 2006). Based on a review of the literature, the most
commonly employed techniques for molecular typing include restriction fragment length
polymorphism (RFLP), ribotyping, random amplified polymorphic DNA (RAPD),
pulsed-field gel electrophoresis (PFGE), arbitrarily-primed PCR (AP-PCR), and
repetitive element PCR (rep-PCR).
Various factors of each technique determined their acceptability for clinical use.
Lack of reproducibility has hampered clinical application of AP-PCR and RAPD
(Struelens, 1998; Wu & Della-Latta, 2002). RFLP was too labor intensive for daily
clinical use, and ribotyping only provided moderate discriminatory power compared to
the other techniques (Struelens, 1998). PFGE was considered the gold standard for many
years, but there are several factors that make this technology less than ideal for the
clinical laboratory. PFGE requires a two to four day turnaround time, is costly to
perform, is labor-intensive, and requires specialized expensive equipment (Struelens,
1998; Wu & Della-Latta, 2002). In contrast, the major complaint of rep-PCR was that the
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technology lacked standardization (Wu & Della-Latta, 2002) while others suggested the
improved reproducibility of the technology would lend itself to standardization as a
library typing system (Struelens, 1998). The benefit is that rep-PCR is the most rapid of
all the technologies currently available for molecular typing (Kang & Dunne, 2003). The
issues with standardization would later be remedied by the introduction of the DiversiLab
system (Healy et al., 2005). The DiversiLab system offered several improvements to the
rep-PCR process including optimized PCR chemistry provided in a reagent kit format,
microfluidics-based DNA amplicon detection, and internet-based computerized analysis
and data storage.
When reviewing studies in molecular typing, the definitions of clones and strains
become important. Clones are defined as genetically related isolates that are
indistinguishable or so similar to each other that they are presumed to descend from a
common parent, and a strain is an isolate or group of isolates that can be distinguished
from other isolates of the same genus and species (Tenover et al., 1995).
Indistinguishable or closely related isolates should have no more than a two to three band
difference (absence or presence of a band), isolates that are possibly related would have a
four to six band difference, and those isolates that are clearly different, considered
distinguishable, would have a seven or greater band difference (Tenover et al., 1995).
Pulsed-field gel electrophoresis is performed by digestion of chromosomal DNA
with rare-cutting restriction enzymes and analysis of the resulting series of fragments by
agarose gel electrophoresis (A. Singh et al., 2006). The “pulsed-field” is obtained by
constantly changing the direction of the electrical field during electrophoresis. PFGE has
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been used in clinical molecular typing studies in many institutions and has been
instrumental in the discovery of outbreak situations. PFGE typing in a neonatal intensive
care unit determined a clonal relationship between the strains of Serratia marcescens
isolated from the patients and those found in the hand washing disinfectant used by the
nursing staff (Villari, Crispino, Salvadori, & Scarcella, 2001). The outbreak was
contained by isolating each of the patients infected with S. marcescens and by more
diligent hand washing and glove use by the staff. PFGE was also shown to identify two
endemic strains of methicillin-resistant Staphylococcus aureus (Petersdorf, Oberdorfer, &
Wendt, 2006) and a cluster of Enterobacter cloacae associated with a high mortality rate
(Kuboyama, de Oliveira, & Moretti-Branchini, 2003). In another example of molecular
typing of antibiotic resistant organisms, PFGE identified a strain of vancomycin-resistant
Enterococcus faecium that was present in 85% of the samples typed (Deplano et al.,
2007). The implementation of weekly surveillance cultures and the increased use of
barrier precautions were effective in controlling the spread of the strain in the hematology
unit of the hospital.
While PFGE has long been considered the gold standard for molecular typing,
improvements in rep-PCR have made the technology more appealing to advanced
laboratories. Repetitive element PCR capitalizes on the widespread distribution of
repetitive DNA elements throughout the genomes of many microorganisms (Versalovic,
Koeuth, & Lupski, 1991). By positioning amplification primers in these repetitive
regions, amplified fragments of various lengths and quantities are produced leading to a
unique molecular fingerprint for each strain of a particular species. Rep-PCR has been
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significantly improved by the introduction of bioMerieux’s DiversiLab system. The
complete DiversiLab system offers quality-controlled reagents in a kit format,
microfluidics-based amplified fragment detection, and internet-based computer assisted
analysis, reporting, and data storage (Healy et al., 2005). The level of discrimination and
reproducibility of the technology paired with the electronic storage of data created an
ideal environment for the archiving of rep-PCR data for comparative longitudinal and
epidemiological studies.
Several studies have compared the discriminatory power of rep-PCR with other
techniques for molecular typing. One study compared PFGE, rep-PCR, and AP-PCR for
typing of Bartonella henselae and found that PFGE and rep-PCR had the highest
discriminatory potential (Sander, Ruess, Bereswill, Schuppler, & Steinbrueckner, 1998).
Another study compared rep-PCR and RFLP for the typing of Pseudomonas isolates from
soil and concluded that rep-PCR performed just as well as RFLP (Cho & Tiedje, 2000).
A comparison of rep-PCR, PFGE, and ribotyping in Clostridium difficile found a high
correspondence between rep-PCR and PFGE results but lesser discrimination with the
ribotyping results (Spigaglia & Mastrantonio, 2003).
Multiple investigators chose to perform a direct comparison between PFGE and
rep-PCR. Candida albicans was a specific pathogen of interest, and rep-PCR was found
to be comparable to PFGE (Chen, Lo, Lin, & Li, 2005). One study showed that the
DiversiLab rep-PCR system was more rapid and conducive to ongoing epidemiologic
studies in Candida species (Wise et al., 2007). The DiversiLab system was also evaluated
for typing of Staphylococcus aureus strains, and the study found that rep-PCR provided
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more consistent results as compared with PFGE and was also less labor intensive (Shutt,
Pounder, Page, Schaecher, & Woods, 2005). Further studies confirmed the comparable
discriminatory power and more rapid turnaround time of rep-PCR as compared to PFGE
in reports of Listeria monocytogenes (Chou & Wang, 2006) and vancomycin-resistant
Enterococcus (Pounder et al., 2005).
Rep-PCR is a proven technology for typing of various bacterial species. Published
studies used rep-PCR to type Acinetobacter baumanii (Martin-Lozano et al., 2002) and
Vibrio vulnificus (Chatzidaki-Livanis, Hubbard, Gordon, Harwood, & Wright, 2006) as
well as several other bacteria isolated from the International Space Station (Castro,
Thrasher, Healy, Ott, & Pierson, 2004). One study that separated Listeria monocytogenes
isolates into four separate clusters suggested that molecular fingerprints be considered
different if there was a discrepancy (presence or absence) of at least two bands (Jersek et
al., 1999). A larger study that evaluated the relatedness of several organisms
(Acinetobacter sp., Enterobacter sp., and coagulase-negative Staphylococcus) between an
individual’s hands and the immediate environment stated specific criteria for the
identification of clusters (Pancholi et al., 2005). Interestingly, greater than 25% of the
bacterial isolates found on the hands and the immediate environment of a single
household were found to be the same strain. Different isolates were defined as those with
less than 95% similarity and a 2-3 band difference. Similar isolates were described as
those with less than 97% similarity but only 1-2 bands difference; and indistinguishable
isolates were defined as those with greater than 95% similarity and no band differences
including intensities. Overall profile intensity differences were acceptable because that
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indicated a universal change throughout the whole rep-PCR profile most likely due to
efficiency of the PCR rather than actual differences between the bacterial isolates.
In addition to bacterial typing, rep-PCR has been recommended as an effective
tool for the typing of fungi (Healy et al., 2004) and dermatophytes (Pounder et al., 2005).
Most importantly, rep-PCR has been proven for use in infection control investigations.
Rep-PCR of vancomycin-resistant Enterococcus was instrumental in the control of an
outbreak in the neonatal intensive care unit (NICU) in one hospital (N. Singh, Leger,
Campbell, Short, & Campos, 2005). In another institution, rep-PCR epidemiologically
linked a NICU outbreak of methicillin-resistant Staphylococcus aureus to a health care
worker afflicted with chronic otitis externa and nasal colonization with a specific MRSA
clone (Bertin et al., 2006).
A recent study compared PFGE to rep-PCR for typing of P. aeruginosa, including
several isolates from patients with CF (Doleans-Jordheim et al., 2009). Rep-PCR was
found to be comparable to PFGE, and the grouping of isolates was consistent when
adhering to a 95% similarity cut-off to define a clonal group. The CF isolates included
isolates from three families, and all isolates within each family were found to be identical
whereas the molecular profiles between families were found to be unique.
Molecular Typing of Burkholderia cepacia in Cystic Fibrosis
Molecular typing of Burkholderia cepacia in patients with cystic fibrosis has been
performed in several centers. An early study discovered epidemic strains in a Toronto CF
center using RFLP and PFGE (Sun et al., 1995). RAPD analysis confirmed an epidemic
strain among multiple patients with CF across the United Kingdom and eastern Canada
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(Mahenthiralingam, Simpson, & Speert, 1997). Additional studies using RAPD and repPCR found cross-infection of the B. cepacia complex across several European cystic
fibrosis centers (Coenye, Spilker, Van Schoor, LiPuma, & Vandamme, 2004);
(McDowell et al., 2004). Similarly, a combination of rep-PCR and PFGE was utilized to
confirm clusters of B. cepacia complex in several CF centers in the United States
(Biddick, Spilker, Martin, & LiPuma, 2003).
Molecular Typing of Pseudomonas aeruginosa
One of the earliest methods used to type strains of Pseudomonas aeruginosa was
pyocin typing. Pyocin is a bacteriocin, a toxin produced by bacteria that inhibits growth
of similar or related species, produced by P. aeruginosa (Higerd, Baechler, & Berk,
1967). Pyocin typing was based on the level of pyocin activity in the isolate and while it
performed better than serotyping, it proved much less accurate than results obtained with
primitive molecular methods (Fyfe, Harris, & Govan, 1984). By the mid-1990s,
molecular typing relied largely on PFGE technology. Comparison studies specific to the
typing of P. aeruginosa showed PFGE to have better discriminatory power than RFLP
(Grundmann, Schneider, Hartung, Daschner, & Pitt, 1995) while a separate study
confirmed that rep-PCR had a level of discrimination equal to PFGE in the typing of P.
aeruginosa (Lau et al., 1995). Utilizing microfluidics chips in conjunction with rep-PCR
was suggested as the most rapid and automated method for typing of P. aeruginosa
(Jamasbi, Kennel, Waters, Foote, & Ramsey, 2004).
PFGE of P. aeruginosa uncovered eight cases of cross-colonization in an
intensive care unit (Bergmans et al., 1998) as well as a clonal infection in a NICU linked
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to artificial nail colonization of a health care worker (Foca et al., 2000). Across four
French intensive care units, carriage of or infection with P. aeruginosa was determined to
be a result of transmission between patients 50% of the time based on PFGE analysis
(Bertrand et al., 2001). The same study documented that patients who were carriers,
colonized, or infected with P. aeruginosa had a significantly longer median stay in the
ICU, 26.3 days versus 7.4 days. P. aeruginosa was also identified in several water faucets
in health care institutions. PFGE led to the discovery of a common clone in an ICU, and
infection control measures, including the replacement of water faucets and reiteration of
hand-hygiene recommendations, were found to decrease the colonization rate (Petignat et
al., 2006). Similarly, a cluster of multiply-resistant P. aeruginosa detected by AFLP
typing was eliminated only when water taps were pasteurized weekly and sterile water
was employed for use with gastric tubes (Bukholm, Tannaes, Kjelsberg, & SmithErichsen, 2002). The MRPA outbreak strain was also found to be significantly associated
with patient mortality. A molecular typing project utilizing PFGE for the typing of
MRPA found one genotype at four different hospitals in Rio de Janeiro (Pellegrino et al.,
2002). The researchers suspected that inadequate infection control practices were the
culprit behind the spread but also suggested that certain MRPA clones may be more
equipped to spread among susceptible hosts in a health care setting. These clones may
exhibit prolonged survival in the outside environment and could further adapt to the
geographic region or ethnicity of the host.
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Molecular Typing of Pseudomonas aeruginosa in Cystic Fibrosis
Attempts were made to type Pseudomonas aeruginosa in patients with cystic
fibrosis as early as the late 1980s. Initial methods included early versions of molecular
technology, pyocin typing, serotyping, and ribotyping. Many of those methods proved
relatively unreliable in later years, so the results of the studies cannot be considered
conclusive given the advances made in the past 20 years. As expected, even the early
typing studies did see related strains present in siblings (Grothues, Koopmann, von der
Hardt, & Tummler, 1988) or with patients attending the same summer camps (Wolz et
al., 1989). An early comparison between pyocin typing and RFLP analysis did confirm
cross-colonization by indicating that 43% of patients typed shared a common genotype,
and the authors agreed that RFLP was a more reliable method than pyocin typing (Fegan,
Francis, Hayward, & Fuerst, 1991). However, even as late as the mid-1990s, laboratories
were still evaluating strains of P. aeruginosa based on phenotypic differences rather than
strain typing (Mahenthiralingam, Campbell, Foster, Lam, & Speert, 1996).
Since genotyping quickly proved superior to phenotyping for detecting
differences between bacterial strains, RAPD and PFGE analysis became the techniques of
choice for typing Pseudomonas aeruginosa in patients with cystic fibrosis in the 1990s;
but there was lingering concern about standardization of interpretation (Renders et al.,
1996). To address reproducibility of results, a study comparing RAPD typing to previous
PFGE results found that the results for individual patients remained closely related but
did display a shift over time (Kersulyte et al., 1995). The project also found related
strains in patients that were visiting the same clinic during the same time period. As
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indicated in earlier publications, PFGE identified a clone that was present in the tap
water, sinks, wash basins, and creams of a CF ward only to discover that the predominant
strain had spread into the adjacent non-CF control ward four years later (Bosshammer et
al., 1995). In contrast, a Danish CF center utilizing PFGE documented that none of their
patients were infected with strains of P. aeruginosa that were similar to the
environmental isolates leading them to conclude that their contact isolation and other
infection control precautions were effective in preventing environmental contamination
with P. aeruginosa (Zembrzuska-Sadkowska, Sneum, Ojeniyi, Heiden, & Hoiby, 1995).
When considering antibiotic resistance, a CF center in the United Kingdom found by
PFGE that 85% of their patients infected with P. aeruginosa appeared to have the same
beta-lactam antibiotic resistant strain (Cheng et al., 1996).
Social interaction both within and outside of healthcare institutions has been a
documented cause of transmission of P. aeruginosa in patients with cystic fibrosis. PFGE
detected that 12 of 40 patients who acquired P. aeruginosa during a period of four years
contracted it from camps, clinics, or rehabilitation centers (Tummler et al., 1991). The
introduction of new infection control practices led to the detection of only one case of
transmission in the CF ward during a two year period, leading the researchers to conclude
that nosocomial transmission significantly contributes to the prevalence of P. aeruginosa
in cystic fibrosis. Camps specifically for patients with CF were later recognized as
significant risk factors for the transmission of P. aeruginosa. While one study did
document no related strains by RAPD analysis at a summer camp and only one case of
acquisition (Hoogkamp-Korstanje, Meis, Kissing, van der Laag, & Melchers, 1995), a
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more recent study found evidence by PFGE of significant transmission, 17 of 22
campers, of a pan-susceptible strain of P. aeruginosa by PFGE once the patients returned
from camp (Ojeniyi, Frederiksen, & Hoiby, 2000). Social interaction can occur even
during inpatient stays as discovered in a study stating that four patients became
superinfected with the same strain of P. aeruginosa after inpatient social contact
(McCallum et al., 2001). This finding led the clinic to type each patient infected with P.
aeruginosa and separate the inpatients colonized with the epidemic strain. Camps for
patients with CF have been discontinued in the United States, but a study of camps in the
Dead Sea region of southern Israel demonstrated that cross-infection among patients
could be eliminated by meticulous separation of individuals (Greenberg et al., 2004).
Social circumstances where separation is impossible such as family life also contributes
to colonization. Cross-transmission of bacterial pathogens in siblings with cystic fibrosis
is well documented (Speert et al., 2002), but a more interesting case described the chronic
colonization of two previously healthy parents with the same P. aeruginosa strain as their
daughter with CF (McCallum et al., 2002).
While a multitude of studies confirmed genetic relationships between strains of P.
aeruginosa in patients with CF, it is appropriate to note that several studies have not
yielded evidence of cross-transmission. A CF center in Leipzig stated cross-colonization
was rare by PFGE (Spencker et al., 2000). Similarly, RAPD analysis suggested that
cross-infection was uncommon in an outpatient clinic in Brazil, but the study only
spanned six months (da Silva Filho et al., 2001). A separate study in Brazil came to the
same conclusion when PFGE typing revealed 39 distinct fingerprint patterns from 41
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patients (Silbert et al., 2001). The two remaining patients were siblings harboring the
same strain of P. aeruginosa, and the authors also noted that mucoid and non-mucoid
strains of P. aeruginosa from the same patient exhibited the same molecular profile in the
majority of cases. A separate study also confirmed that mucoid and non-mucoid P.
aeruginosa isolates from the same patient produced the same pattern (Campana et al.,
2004). Additionally, a CF clinic in North Staffordshire found no evidence of crossinfection with the environment or between patients except in the case of siblings (Tubbs
et al., 2001). Even one recent study in New Delhi, India that utilized a form of rep-PCR
found 26 of 27 P. aeruginosa isolates to be unique (Agarwal et al., 2005).
Several studies have reported lack of evidence by molecular typing of
transmission of P. aeruginosa between patients with CF, but the majority of recent
studies have found evidence of cross-infection including several publications from the
United Kingdom. Analysis of patients in the Manchester Adult CF unit by PFGE
discovered that 14% of patients harbored the same strain, which happened to be solely
composed of multiply-resistant P. aeruginosa isolates in either the mucoid or non-mucoid
form (Jones et al., 2001). The clinic also typed P. aeruginosa isolates from non-cystic
fibrosis patients, and those isolates were found to be unique strains. Further research into
the patients infected with the epidemic strain revealed no common demographic factor
but confirmed that 23 of the 24 patients with the epidemic strain had been inpatients at
least once in the previous two years. A smaller study reviewed the history of six patients
from a pediatric CF center in the United Kingdom. Four of the patients had overlapping
hospital stays, and PFGE analysis produced identical genotypes for those four patients

45
and unique profiles for the other two patients (Denton et al., 2002). In addition, a large
study of CF centers across England and Wales found evidence of cross-infection between
and within centers (Scott & Pitt, 2004).
Several publications documenting evidence of cross-infection of P. aeruginosa
have also originated from Australian cystic fibrosis clinics. An initial probing of patient
samples by PFGE found that greater than one third of patients were infected with the
same P. aeruginosa strain in an adult CF center (Anthony et al., 2002). A similar study
focusing on a pediatric CF center showed that 55% of patients shared a genetically
related strain (D. S. Armstrong et al., 2002). Interestingly, two environmental surveys
performed four years apart failed to detect the clonal strain, and analysis of patient data
determined that infection with the clonal strain was not associated with adverse clinical
outcomes. The results of these studies led to molecular typing, by PFGE and RAPD,
across five CF clinics in Australia. An identical clone, a mucoid multiply-resistant P.
aeruginosa, was discovered in all five clinics and was found to be the dominant clone in
three of the clinics (D. Armstrong et al., 2003). A more recent analysis of an adult and
pediatric CF center by rep-PCR and PFGE confirmed a dominant clone infecting 38% of
the patients with P. aeruginosa (Syrmis et al., 2004). This particular study also defined
profiles with two or more band differences as unrelated.
A recent publication described the environmental pathogen risk in an Italian
outpatient cystic fibrosis clinic (Festini et al., 2007). Pathogens found on environmental
surfaces included Pseudomonas aeruginosa, Staphylococcus aureus, Achromobacter
xylosoxidans, Stenotrophomonas maltophilia, and Burkholderia cepacia. P. aeruginosa

46
was found in 22.8% of environmental samples, and the estimated risk for a non-colonized
patient coming in contact with P. aeruginosa from clinic surfaces was 5.4% for each
visit. RAPD analysis confirmed the relationships between environmental and patient
isolates, and the authors suggested complete disinfection of visiting room surfaces and
availability of alcohol rubs to reduce the risk of transmission.
Newer studies have evaluated patient outcomes based on the specific clonal strain
identified. Researchers in the United Kingdom developed an assay to specifically detect
the Liverpool epidemic strain of P. aeruginosa, and analysis of patient data revealed
patients with the epidemic strain had a greater loss of lung function and a deteriorating
nutritional state as determined by FEV1 and BMI, respectively. These patients also
demonstrated a greater need for admittance to the hospital and additional days of
antibiotic treatment (Al-Aloul et al., 2004). Another study in an Australian pediatric
clinic documented that 43% of patients with cystic fibrosis acquired P. aeruginosa before
they reached seven years of age. The study also identified a strain of MRPA infecting
seven children, four of whom died due to the increased morbidity associated with the
strain (Nixon et al., 2001). Overall the study confirmed that patients with a history of
Pseudomonas aeruginosa infection had lower average FEV1 values and spent more time
in the hospital. Interestingly, the study also found no difference in patient outcomes for
mucoid versus non-mucoid forms of P. aeruginosa. Analysis of a patient group in the
United Kingdom by PFGE also identified two epidemic strains, the Liverpool and
Sheffield strains, in patients that led to higher morbidity and more treatment as opposed
to patients infected with unique strains (Edenborough et al., 2004). A large study across
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several adult and pediatric CF centers in Australia revealed 59% of patients shared a
common P. aeruginosa strain not found to be MRPA (O'Carroll et al., 2004). When
compared to unique strains, those infected with the clonal strain were younger, exhibited
poorer lung function by FEV1, and required more days in the hospital (26.5 days versus
12 days). If patients were infected with an additional strain besides the clonal strain, the
patient was still classified as having the clonal strain. In addition, the researchers stated
that minor clonal strains that included two or more patients should still be deemed a
cluster.
The review of the literature revealed that no study specifically focused on
molecular typing of multiply-resistant P. aeruginosa in patients with cystic fibrosis.
While some studies discovered a clonal strain that proved to be MRPA, their dataset also
included patients infected with susceptible P. aeruginosa. In addition, few of the studies
described multi-year molecular analyses or used rep-PCR as their molecular technique of
choice. A comprehensive study that includes the most advanced molecular techniques,
several years of data, and analysis of patient outcomes based on clonal group is needed.
A preliminary study identified a dominant MRPA clone present in patients with
cystic fibrosis at Texas Children’s Hospital. The dominant clone included patients seen
over the course of several years, and no clear pattern of association was evident between
the patients. Ongoing molecular typing of MRPA isolates from patients with CF was
requested by the CF Center and the Infection Control department of Texas Children’s
Hospital, and additional analyses of patient-related variables as they relate to clonality
were desired.
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The patient-related variables selected for inclusion in the study were based on
multiple references highlighting the potential significance of each variable. While an
ongoing large multi-center clinical trial aims to identify additional risk factors for
acquisition of P. aeruginosa (Treggiari et al., 2009), two studies presented data
supporting the inclusion of variables related to gender, CF genotype, culture results, lung
function, and hospitalization rate (Levy et al., 2008; Maselli et al., 2003). Many early
references noted gender, specifically females, as a risk factor for acquisition of P.
aeruginosa (Demko, Byard, & Davis, 1995). Exposure to CF clinics, BMI percentile, and
the mother’s educational level were also implicated as risk factors by separate studies
(Farrell et al., 1997; Kosorok et al., 1998; McPhail, Acton, Fenchel, Amin, & Seid, 2008;
Watts et al., 2009). In addition to hospitalization rate and clinic visits, another study
documented the added risk of tobramycin use (Merlo et al., 2007). Initial infection with
other pathogens, such as Staphylococcus aureus was shown to contribute to infection
with P. aeruginosa (Lyczak, Cannon, & Pier, 2000). An early diagnosis of CF has been
shown to affect the time of acquisition of P. aeruginosa (D'Alessandro, Renteria,
Fernandez, Martinez, & Segal, 2009; Kappler, Feilcke, Schroter, Kraxner, & Griese,
2009; Rodman et al., 2005), and the patient’s age at the time of infection has been found
to potentially impact the clone acquired (van Mansfeld et al., 2009). A large study
utilizing national data from the CF Foundation patient registry selected FEV1, BMI, and
annual hospitalization rate as important indicators of a patient’s overall health status
(Zemel, Jawad, FitzSimmons, & Stallings, 2000). In regards to patient outcomes, P.
aeruginosa infection has consistently been shown to affect lung function (FEV1) and
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BMI. Finally, several studies have presented data confirming that infection with a
specific P. aeruginosa clone can negatively impact patient outcomes (Al-Aloul et al.,
2004; Bradbury, Champion, & Reid, 2008; Edenborough et al., 2004; Nixon et al., 2001;
O'Carroll et al., 2004).
Patients with cystic fibrosis are expected to become chronically infected with P.
aeruginosa at some point in their lives. However, adequate diagnosis, prevention, and
treatment could contribute positively to both quality of life and longevity. By evaluating
patient-related variables and patient outcomes as they relate to MRPA clones, additional
information will be obtained that could be translated into new treatment and prevention
guidelines. Identification of risk factors for acquisition of the dominant MRPA clone
could contribute to future infection control strategies. Differences in patient outcome
based on infection with the dominant MRPA clone could also tailor future clinical
practice guidelines, such as treatment with more aggressive antimicrobials.

CHAPTER 3: METHODOLOGY

This chapter will discuss the following topics related to the methodology of the
study: research design, subjects, variables, human studies protocol, data collection, data
analysis, validity, and limitations. The purpose of this study is to discover relationships
between patient-related variables and infection with multiply-resistant Pseudomonas
aeruginosa (MRPA) in cystic fibrosis. The specific research questions addressed by this
study include:
Is infection with the dominant MRPA clone related to patient-related variables
prior to MRPA infection?
Is patient outcome related to infection with the dominant MRPA clone?
The following hypotheses are proposed by this study:
HO1: Patient-related variables prior to MRPA infection are correlated to infection with
the dominant MRPA clone.
HO2: Infection with the dominant MRPA clone is correlated to patient outcome.
Research Design
A non-experimental ex post facto design was employed for this study. Polit and
Beck (2004) describe this type of study as when “the researcher observes phenomena as
they naturally occur without intervening.” The study was a comparison of patient-related
variables between two groups of patients with cystic fibrosis (CF), those infected with the
50
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dominant MRPA clone and those infected with a non-dominant MRPA clone. Due to the
potential impact on patients, a true experimental study was not possible with this research
topic. The ex post facto design is ideal for retrospective studies, and while it cannot
establish causality, it can estimate how much of the variation in the dependent variable
can be predicted from the variation of the independent variable (Polit & Beck, 2004). For
the evaluation of possible risk factors for infection with the dominant MRPA clone, the
independent variables are patient-related variables prior to infection with MRPA and the
dependent variable is the MRPA clone (dominant or non-dominant). Conversely for the
comparison of post-infection differences between the two clonal groups, the independent
variable is the MRPA clone (dominant or non-dominant) and the dependent variables are
patient outcomes following infection with MRPA.
Several assumptions were made in developing this study including that all patientrelated variables and patient outcome data were correctly entered into Port CF, the
electronic national repository for CF patient data (FitzSimmons, 1993). It was also
assumed that measurement of patient data, such as FEV1 and weight, was accurate and
precise. In regards to the accuracy of laboratory data, it was assumed that no MRPA
infections were missed by respiratory culture and that all rep-PCR molecular profiles
were accurate. In addition, the study assumed that all MRPA isolates from patients with
CF who were eligible for the study were submitted for molecular typing.
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Design Quality
Internal Validity
The following specifically addresses threats to internal validity that might
compromise the ability to infer that the dependent variables are related to the independent
variables. The variables included in the research design were intended to account for any
history that may affect the outcome. Variables were selected for this intent based on
conclusions from a thorough literature review (Al-Aloul et al., 2004; Edenborough et al.,
2004; Emerson et al., 2002; Kosorok et al., 1998; Nixon et al., 2001). It is possible that
additional variables exist that may contribute to the acquisition of MRPA, but the study
was limited by the data fields collected and entered into Port CF. Additional factors not
recorded in the patient registry that may be significant include social interaction both in
and out of the hospital or clinic, specific hospital or clinic rooms utilized, and
practitioners seen at each visit. The independent variables associated with the first
research question document the important historical and demographic factors of the
patient’s illness, and these factors were then tested against whether or not the patient has
been infected with the dominant MRPA clone.
Because the patients were not randomized into groups and instead were grouped
by which MRPA clone infected them, no selection bias was present. The study was
designed to identify variables that contributed to infection with one of the two clonal
groups. The data spanned the course of a few years for some of the patients, so physical
maturation or childhood development could be a concern. However, the changes in the
patients that are not thought to be associated with infection by the dominant MRPA clone
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should be random for patients in either group as these changes would be part of the
natural disease progression, ex., steadily declining lung function that is characteristic of
CF. In addition, quantitative patient outcome variables were normalized for the passage
of time by calculating hospitalization rates per year and changes in BMI and FEV1
percentiles per month or per year.
The results of the study cannot be affected by testing because all testing was
performed as part of routine clinical care for patients with CF. Instrumentation threats
were controlled by using clinically validated technologies and previously evaluated
commercially available reagents and data analysis software (Healy et al., 2005). The
utility of rep-PCR in differentiating strains of the same bacterial species is well
documented in the literature with multiple comparisons to PFGE, the gold standard
(Chou & Wang, 2006; Doleans-Jordheim et al., 2009; Jamasbi et al., 2004; Pounder et al.,
2005; Shutt et al., 2005). At the time of the proposal of this study, a thorough literature
review showed that no published study specifically focusing on MRPA had utilized repPCR. However, there have been studies that confirmed the performance of rep-PCR for
P. aeruginosa in patients with CF (Agarwal et al., 2005; Doleans-Jordheim et al., 2009;
Syrmis et al., 2004). In addition, rep-PCR technology continues to meet the College of
American Pathologist’s guidelines for utility in a clinical setting, including quality
assurance metrics and proficiency testing.
Patient mortality should not threaten the integrity of the study. While patients in
the study succumbed to illness, data obtained before death was included in the analysis,
and death was measured as a dependent variable for the second research question (which
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asks if patient outcome is related to infection by the dominant MRPA clone). Death
would not affect the other patient outcome variables because clinical data would have
been collected at the next evaluation following MRPA infection, and hospitalization rate
accounts for the number of days hospitalized per year (including fractions of a year). The
only rare situations where patient mortality would affect the ability to collect patient data
would be if a patient died less than one month after MRPA diagnosis (preventing the
collection of the post-MRPA infection data). No patients in the study met this criterion.
External Validity
The study design also showed few weaknesses with respect to threats to external
validity. Because there was no interaction with the patients beyond routine clinical care,
no expectancy effects, novelty effects, experimenter effects, or measurement effects were
identified with respect to testing. The most significant threat noted with external validity
was the possibility of interaction of history and its effect on treatment due to
undocumented contact between patients, such as social interactions. While social
interactions during inpatient stays are carefully monitored and discouraged by hospital
staff, contact outside of the hospital is certainly plausible. Contact of TCH patients with
patients from other CF centers including the adult CF Clinic is also possible and would
threaten external validity as well. It is possible that the results of this study could not be
generalized to other CF centers and CF populations. The dominant MRPA clone could
possibly be a geographical anomaly that is only present at TCH or could be related to a
specific clinic or hospital process in this center. The CF Foundation has published
numerous consensus statements regarding treatment of patients, and the foundation
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inspects each accredited CF center (Saiman & Siegel, 2003, 2004; www.cff.org).
However, it is still reasonable to note that subtle differences in practice could contribute
to the proliferation of this MRPA clone in this specific population, which would be
considered a threat to external validity due to the inability to apply the study results to
other CF centers.
Statistical Validity
Missing data was a threat to statistical validity, but missing data points were
randomly observed within this dataset. Patient data is required to be reported in Port CF
for each hospital or clinic visit, so by only accepting patients who have consented to have
their information documented in Port CF, the study controls for this factor as much as
possible. Patients with missing data points were removed from the analyses involving the
particular variable for which data was unavailable.
Statistical power could not be calculated prior to analysis because effect size
could not be estimated. Statistical power based on the sample size that was obtained and
the resulting statistical output was calculated as a post hoc analysis using nQuery Advisor
7.0 (Statistical Solutions, Saugus, MA). Each individual model tested by logistic
regression was analyzed by nQuery using the resulting R2 value and an alpha level of
0.05.
Significant predictors (patient-related variables) of infection with the dominant or
a non-dominant MRPA clone could ultimately be responsible for changes in patient
outcome. The scope of this study, specifically the limited patient population, does not
provide the ability to definitively determine whether the predictor variables or the
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specific MRPA clone were ultimately more responsible for poor patient outcomes. By
determining which of the factors are significant, larger studies exploring specific
predictors of patient outcomes in multiple CF centers could be performed.
Subjects
The population of interest for this study was all patients of the CF Care Center at
Texas Children’s Hospital from 2004 through early 2009. This study utilized a nonprobability convenience sample and was specifically intended for patients of the CF Care
Center that were diagnosed with a MRPA infection during the course of the study (typing
data obtained from October 2004 through January 2009). Inclusion criteria were that
patients have documented MRPA infection and that data relevant to particular patientrelated variables are available through Port CF or through medical records at TCH. Port
CF is the national patient registry established by the Cystic Fibrosis Foundation as a
resource for physicians and researchers (FitzSimmons, 1993; Zemel et al., 2000). Patients
were deemed eligible for the study if they satisfied the following requirements: patient
background data was available through Port CF (handling of missing data points is
addressed under statistical validity), patient information collected at a clinic or hospital
visit just prior (no greater than 6 months) to infection with MRPA was available, patient
information collected at a clinic or hospital visit following diagnosis of MRPA infection
(at least one visit 1-6 months following infection) was available, and MRPA isolates were
submitted to the Molecular Microbiology laboratory for DNA typing.
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Variables
Pediatric patients were routinely seen at the CF clinic at least four times per year.
During a patient’s initial visits, patient data was captured in Port CF with their consent.
The categorical variable responsible for creating the two groups analyzed in this study is
whether or not the patient has been infected with the dominant MRPA clone. The clone
designation was made based on results of DNA typing. In cases where a patient was
infected with the dominant MRPA clone as well as another clone, patients were
considered members of the dominant MRPA clone group. New MRPA isolates were
added to the cumulative dendrogram produced during the course of the epidemiological
study at the hospital. If a patient had a previous MRPA infection and thus a previously
typed MRPA isolate, then the new MRPA isolate was checked against that patient’s older
MRPA isolates to ensure the patient remained in the same clonal group (i.e., dominant
MRPA clone or non-dominant MRPA clone). Some patients were initially infected with a
unique MRPA clone (non-dominant clone group) but later became infected with the
dominant MRPA clone. Once infection with the dominant MRPA clone was confirmed,
the patient data was included in the dominant MRPA clone group only.
The variables selected for the study were based on multiple references detailing
clinical significance and are summarized in Figure 1. It has been noted that disease
severity is highly impacted by CF genotype. In addition, gender is significant due to
poorer survival rates in females. Several factors including age at the time of initial CF
diagnosis, chronological age, hospitalization rate, and mother’s educational level are
known contributors to infection with P. aeruginosa. Inhaled tobramycin use is also
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Patient-related variables
prior to MRPA infection
Age at CF Dx
Age at MRPA
Dx
BMI

Patient outcome variables
following MRPA infection

FEV1

∆FEV1

Days
Hospitalized
CFTR Genotype

∆BMI
Clone

Mother’s Ed

Hospital/year

Gender

Death

Clin-MRPA
Tobramycin
Culture result
Hosp-MRPA
Figure 1. Patient-related Variables and Patient Outcome Variables.
Note: The patient-related variables and the patient outcome variables are collected in Port CF. The clone
variable is obtained through molecular typing.

suspected as a contributor to the emergence of MRPA. Infection with MRPA is
associated with a higher risk of mortality, and FEV1 and BMI are widely accepted
predictors of survival in patients with CF.
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Patient-related Variables as Risk Factors for Clone Acquisition
Patient-related variables recorded prior to MRPA infection were obtained from
Port CF. Data for variables collected from the clinic visit just prior to MRPA infection
were required for inclusion of that patient in the study. The visit just prior to MRPA
infection is defined as a hospital or clinic visit just before (but within six months of) the
visit during which MRPA was diagnosed. The independent variables for this research
question include a variety of patient data such as demographic information and diseasespecific characteristics. The data was readily available for the majority of study patients
as patients with CF are seen quarterly in addition to hospital or clinic visits due to illness.
The dependent variable for this research question is the MRPA clone (dominant or nondominant). All variables included in the analysis of patient-related variables as risk
factors of dominant MRPA clone acquisition are listed in Table 2.
Differences in Patient Outcome Based on MRPA Clone
All post-MRPA infection patient-related variables were obtained from Port CF.
Data for short-term patient outcome variables collected from the visit after diagnosis with
MRPA infection were required for inclusion of that patient in the study. The visit after
diagnosis with MRPA infection is defined as a hospital or clinic visit after (no sooner
than one month, but no later than six months) the visit during which MRPA was
diagnosed. Data for long-term patient outcomes were collected from the last recorded
clinic visit prior to December 2009, as approved by the IRB. The independent variable
for this research question is the MRPA clone (dominant or non-dominant). The
dependent variables are patient outcome data involving changes in FEV1 and BMI per
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Table 2.
Variables Analyzed in Determination of Potential Risk Factors of Dominant MRPA
Clone Acquisition
Variable
type
Categorical

Quantitative

Unit of measurement
or coded categories
1 for dominant MRPA
clone, 0 for nondominant MRPA
clone
0 for < age 1, 1 for >
age 1
Years

Quantitative

Percentile

Quantitative

Percentile

Quantitative

Days

Categorical

1 for
delF508/delF508, 2
for delF508/other, 3
for other mutations
0 for less than high
school (HS), 1 for HS
diploma or equivalent,
2 for some college, 3
for college graduate, 4
for unknown
0 for male, 1 for
female

Variable

Definition of variable

Clone

Clone identified by DNA
typing

Age Dx

Quantitative

CFTR
Genotype or
Mutation

Patient age at time of CF
diagnosis
Patient age at time of MRPA
infection diagnosis
Body mass index percentile
based on height and weight at
visit just prior to MRPA
infection
Forced expiratory volume in
one second, volume of air (in
liters) which can be forcibly
exhaled from the lungs in the
one second, expressed as
percentile predicted based on
healthy, non-smoking people
of the same gender and age, at
visit just prior to MRPA
infection
Total number of days
hospitalized in the year prior to
MRPA diagnosis
Mutation combination
responsible for CF identified in
the patient

Mother's Ed

Mother's educational level

Categorical

Gender

Gender of the patient

Categorical

Age MRPA
BMI

FEV1

Days Hosp
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Table 2. Variables Analyzed in Determination of Potential Risk Factors of Dominant
MRPA Clone Acquisition (continued)
Variable
type
Categorical

Variable

Definition of variable

Clin-MRPA

Time between last CF clinic
visit and MRPA diagnosis

Tobramycin

Tobramycin use at visit just
prior to MRPA diagnosis
Respiratory culture result at
visit just prior to MRPA
diagnosis

Categorical

Time between most recent
hospital admission and MRPA
diagnosis

Categorical

Culture result

Hosp-MRPA

Categorical

Unit of measurement
or coded categories
1 for < 60 days, 2 for
61-120 days, 3 for >
120 days
0 for no, 1 for yes
1 for negative culture,
2 for non-MRPA P.
aeruginosa, 3 for P.
aeruginosa (PA) and
MSSA, 4 for PA and
MRSA, 5 for PA and
another organism, 6
for other organism(s)
not PA
1 for <90 days, 2 for
91-180 days, 3 for
181-365 days, 4 for
>365 days

month (short-term outcomes), changes in FEV1 and BMI per year (long-term outcomes),
annual hospitalization rate, and mortality. All variables included in the analysis of
potential differences in patient outcome based on MRPA clone are listed in Table 3.
Measurement Quality
All measurements were performed by clinically validated testing methodologies
in compliance with hospital regulations pertaining to the Joint Commission on
Accreditation of Healthcare Organizations (JCAHO) and laboratory regulations
pertaining to the College of American Pathologists (CAP) and the Clinical and
Laboratory Standards Institute (CLSI). All measured patient data such as age, weight and
height (necessary for BMI calculation), and FEV1 were obtained by trained and
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Table 3.
Variables Evaluating Differences in Patient Outcome Between the Two Clonal Groups
Variable

Definition of variable

Clone

Clone identified by DNA
typing

ΔFEV1/Month Change in FEV1 percentile
between visit just prior to
MRPA diagnosis and visit
after MRPA was diagnosed
divided by the number of
months between visits
ΔFEV1/Year
Change in FEV1 percentile
between visit just prior to
MRPA diagnosis and the last
recorded visit divided by the
number of years between visits
ΔBMI/Month Change in BMI percentile
between visit just prior to
MRPA diagnosis and visit
after MRPA was diagnosed
divided by the number of
months between visits
ΔBMI/Year
Change in BMI percentile
between visit just prior to
MRPA diagnosis and the last
recorded visit divided by the
number of years between visits
Hosp year
Number of days hospitalized
per year after MRPA
diagnosis, calculated as (# of
days hospitalized) /(# of years
data is available), ex. 35 days
hospitalized in 18 months of
follow-up data post MRPA
infection would be 35/1.5 =
23.3
Death
Death of a patient during data
collection period

Variable
type
Categorical

Unit of measurement
or coded categories
1 for dominant MRPA
clone, 0 for nondominant MRPA
clone
Quantitative Percentile

Quantitative Percentile

Quantitative Percentile

Quantitative Percentile

Quantitative Days per year

Categorical

0 for still living, 1 for
death during data
collection period
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knowledgeable staff. All patients are routinely seen by either the CF Care Center staff in
the hospital clinic or the inpatient hospital staff dedicated to Pulmonology at TCH. All
lung function testing (FEV1) was performed by licensed respiratory therapists who
routinely perform these tests on pediatric patients. Calculations for BMI and FEV1 were
performed using pre-determined computer-aided formulas. In addition to the clinical data,
demographic data such as age of the patient, clinic visit and hospitalization dates, CFTR
genotype, mother’s educational level, gender, and tobramycin use were entered into Port
CF by a single well-trained individual.
Sensitivity and specificity for each of the laboratory assays were documented
during the initial validation phase. Biochemical testing and DNA sequencing
methodologies have been validated for abilities to generate meaningful bacterial species
identification (including P. aeruginosa). Antimicrobial susceptibility testing methods
have been validated with respect to classifying isolates as susceptible or resistant to each
antibiotic tested (Clinical and Laboratory Standards Institute, 2005). DNA typing
methodologies (DiversiLab) were validated in terms of abilities to distinguish different
bacterial strains with accuracy, resolution, and reproducibility (Clinical and Laboratory
Standards Institute, 2007). DNA typing of MRPA isolates in patients with CF was
specifically evaluated for reproducibility, and it was found that MRPA isolates from the
same patient with the same clone yielded reproducible DNA profiles by the following
comparisons: repeat testing of the same MRPA DNA on multiple occasions, multiple
MRPA DNA isolations from the same respiratory sample, and multiple MRPA DNA
isolation from different respiratory samples (in many cases, reproducible profile data
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span several years). The reproducibility of molecular typing of MRPA isolates is
illustrated in Figure 2.
a

b

c

d

Figure 2. Reproducibility of MRPA Molecular Typing Profiles.
Note: The highly similar molecular profiles above show the same MRPA clone (strain) in (a) different
specimens from one patient at one collection date, (b) different specimens from one patient on multiple
collection dates, (c) a sibling pair, and (d) a mucoid and non-mucoid isolate from the same patient.
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Human Studies Protocol
This study was approved by the Institutional Review Boards (IRB) of both Baylor
College of Medicine (protocol H-25980) and Virginia Commonwealth University
(protocol HM 12652). No patient interaction was required for this study, and no patient
consent was necessary. All patient information including laboratory results were obtained
through the normal course of treatment for cystic fibrosis (Bush, Alton, Davies,
Griesenbach, & Jaffe, 2006). No compensation to patients was offered. Inclusion and
exclusion criteria were based on availability of data in Port CF.
Patient data was collected from Port CF by the student researcher reviewing each
individual patient record, and each patient was assigned a unique number that only the
researcher could relate back to patient name or medical record number. All patient data
was kept either on secure servers or in locked file cabinets in locked offices. Compliance
to HIPAA standards was maintained at all times. No one besides the researcher,
physicians, and CF Center personnel was allowed access to the patient data. The
document linking patient information with the assigned study number was destroyed at
the completion of the study. No patient identifiers will be reported in any published
version of the study. The results of this study will only be reported as aggregate data.
Data Collection
Laboratory Data
Isolation and Identification of P. aeruginosa
Respiratory samples such as sputa, throat/nasal cultures, and bronchoalveolar
lavages were collected from patients at each visit to the CF clinic and as part of inpatient
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care as recommended by the CF Foundation (Patient Registry 2006 Annual Report, 2008;
Saiman & Siegel, 2003). The samples were submitted to the Microbiology laboratory at
Texas Children’s Hospital for respiratory culture, and routine culture methods were
performed by certified medical technologists. Respiratory samples were cultured on
multiple media (blood agar, chocolate agar, MacConkey agar, PC (Pseudomonas
cepacia) agar, CNA agar (Columbia agar with colistin and nalidixic acid), and
ChromeSA agar) and incubated at 35 C in a 5% CO2 incubator for 24-48 hours. If a bluegreen pigment was detected on the MacConkey or chocolate agar plates due to the
presence of pyocyanin, then the isolate was reported as P. aeruginosa.
If no pigment was detected, then the isolate was tested in the VITEK 2 instrument
(bioMerieux, Durham, NC). A suspension of organisms (density equivalent to a
McFarland No. 0.50 to 0.63) was prepared in a tube of sterile saline and loaded into the
VITEK 2 instrument. The instrument then inoculated a series of pre-formulated wells in
the VITEK 2 Gram-Negative identification card. This particular card contains 47
biochemical tests based on established biochemical methods as well as carbon source
utilization, enzymatic activities, and vibriostatic compound resistance. The VITEK 2
provides an automated result, in terms of relative probability, based on unique organismspecific biochemical profiles for the card loaded on the instrument. The relative
probability is a percentage based on a comparison of the observed reactions in the patient
sample to the typical reactions of each organism intended to be identified by the card. If
the isolate was identified with a relative probability of > 90% P. aeruginosa, then the
isolate was reported as such based on validation of the VITEK 2 system and routine
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culture methods in the Microbiology laboratory at Texas Children’s Hospital. If the
relative probability was < 90%, then the isolate was forwarded to the medical
technologists in the Molecular Microbiology laboratory at Texas Children’s Hospital for
DNA pyrosequencing-based bacterial identification (Luna et al., 2007).
For pyrosequencing-based bacterial identification, bacterial DNA was extracted
using the Mo Bio UltraCleanTM Microbial DNA kit (Mo Bio Laboratories, Inc., Solana
Beach, CA). Amplification using primers specific to the V1 and V6 regions of 16S rDNA
was performed in a master mix reaction containing deoxynucleoside triphosphates,
magnesium chloride, 10X PCR buffer, and Taq DNA polymerase. The amplified product
was then subjected to pyrosequencing, and sequences of 30-40 bases were produced for
each region, V1 and V6. Ribosomal RNA gene sequences were used to search against a
publicly available database, the Ribosomal Database Project (Cole et al., 2005). A final
identification was made by combining DNA sequence and biochemical data.
Determination of Antimicrobial Resistance
Antibiotic susceptibility testing for all P. aeruginosa isolates was performed by
disk diffusion. P. aeruginosa isolates were cultured on Mueller Hinton plated medium,
and antimicrobial-containing disks were placed on the surface of the medium. Antibiotics
tested included tobramycin, gentamicin, amikacin, ciprofloxacin, ceftazidime,
meropenem, piperacillin, ticarcillin/clavulanate, and aztreonam. Based on the zone of
inhibition, the organism was reported as susceptible, indeterminate, or resistant for each
antibiotic tested (Clinical and Laboratory Standards Institute, 2005). MRPA was defined
as being resistant to all antibiotics in two or more of the following groups:
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aminoglycosides (tobramycin, gentamicin, and amikacin), fluoroquinolones
(ciprofloxacin), and beta-lactams (ceftazidime, meropenem, piperacillin,
ticarcillin/clavulanate, and aztreonam) (Lang, Aaron, Ferris, Hebert, & MacDonald,
2000).
Determination of MRPA Clone (Dominant vs. Non-dominant)
When a MRPA isolate was identified from a patient with CF, a glycerol stock was
made and stored at -80°C by the Microbiology laboratory. Every three months, all of the
accumulated MRPA samples were verified as MRPA isolates from patients with CF,
cultured, and forwarded to the medical technologists in the Molecular Microbiology
laboratory of Texas Children’s Hospital for DNA typing.
DNA typing to determine clonal groups present among the MRPA isolates from
patients with CF was performed by rep-PCR (Versalovic et al., 1991). Rep-PCR is a
highly reproducible technology that generates results comparable to PFGE. Studies
involving Staphylococcus aureus (Shutt et al., 2005), Listeria monocytogenes (Chou &
Wang, 2006), and vancomycin-resistant Enterococcus (Pounder et al., 2005) have shown
that rep-PCR was faster and less expensive than PFGE, making the technology more
conducive to the clinical laboratory environment. The DiversiLab system, which utilizes
reagent kits for rep-PCR as well as proprietary software for interpretation, is suitable for
epidemiological studies due to the standardized nature of the technology (Healy et al.,
2005; Wise et al., 2007). The DiversiLab system is used clinically by many molecular
diagnostics laboratories and has been validated for use with multiple organisms including
Pseudomonas aeruginosa. The DiversiLab molecular typing system has been in use
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clinically as a fully validated testing strategy to determine the relative similarities of
bacterial isolates (strains within a single species) at Texas Children’s Hospital since
2003. In addition to validation studies performed at each individual laboratory, the
technology is also subject to proficiency testing through the College of American
Pathologists (CAP). Reproducibility studies were performed to assess the effectiveness of
the typing strategy for P. aeruginosa in patients with CF prior to the initiation of this
study. DNA replicates as well as organism replicates (same culture, separate extraction)
yielded greater than 99% similarity. Cultures obtained from unique specimens from the
same patient also exhibited greater than 99% similarity, and the time between collection
of those specimens varied (from minutes to years).
Quality control of molecular typing reagents was performed at each quarterly run.
Positive P. aeruginosa controls as well as previously tested MRPA DNA extracts were
tested with each batch of samples and verified for adequate profile diversity and
similarity to previous results. Every change in lot number for PCR reagents was verified
for quality by this system, as well as external proficiency testing and technologist
competency testing. Repeat cultures from previously tested patients were also confirmed
regarding previous similarity grouping.
Bacterial DNA was extracted from bacterial colonies using the Mo Bio
UltraCleanTM Microbial DNA kit (Mo Bio Laboratories, Inc., Solana Beach, CA). An
inoculation loop (10 µL) of bacterial cells was scraped from a culture plate and
suspended in the proprietary microbead solution. The suspension was processed through
a series of washes and microcentrifuge spins as described in the procedure manual of the
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extraction kit, and the bacterial DNA was eluted in a final volume of 35 µL. The eluted
DNA was quantitated (ng/µL) and evaluated for purity based on absorbance
spectrophotometry (A260/280 ratio) using the NanoDrop 1000 spectrophotometer
(NanoDrop Products, Wilmington, DE). The NanoDrop 1000 was calibrated regularly
using known concentrations of commercially obtained nucleic acid standards, and two µL
of the eluted DNA was placed on the pedestal of the instrument for measurement.
Rep-PCR was performed using the DiversiLab Pseudomonas fingerprinting kit
(bioMerieux, Durham, NC). Rep-PCR oligonucleotide primers bind to conserved,
interspersed repetitive sequences throughout the bacterial genome, and these primers
direct amplification at multiple primer binding sites to produce multiple DNA fragments
of various lengths, yielding strain-specific DNA profiles. The details of the
oligonucleotides included in the commercial primer mix are proprietary information. The
amplified products were loaded into the DNA LabChip, combined with a proprietary geldye matrix, and size-fractionated by microfluidics and electrophoresis in the Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). The Bioanalyzer uses a series of
wells and microchannels to electrophoretically separate DNA fragments, and each
fragment is detected by laser-induced fluorescence (excitation wavelength of 635 nm,
emission wavelength of 685 nm) of a proprietary dye that intercalates into DNA. The
various sizes and relative intensities of the amplified fragments yield clone- or strainspecific chromosomal DNA profiles.
Automated DNA fingerprinting results were then transferred to the DiversiLab
3.1 software. The software uses the Pearson correlation coefficient and the Unweighted
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Pair Group Method with Arithmetic mean (UPGMA) to compare the presence or absence
of amplified fragments as well as the intensity of each fragment. This analysis leads to
the generation of a dendrogram, similarity matrix, and scatterplot that conveys the
relative similarities of isolates based on the DNA profiles generated by rep-PCR (Figure
3). The dendrogram is a hierarchical tree representation that uses group averages to
display relative similarities or clusters of the isolates. The similarity matrix builds upon
the information provided in the dendrogram by providing a percent similarity for each
node of the tree. The scatterplot is a non-hierarchical data display that uses a twodimensional spatial representation to display relative similarities of isolates by virtue of
relative distances on a grid.
Patient isolates were designated by the researcher as the dominant clone, a unique
clone, or a smaller clone based on relative similarities provided by the similarity matrix.
For the purpose of this study, the isolates were designated as either members of the
dominant clone or a non-dominant clone. For isolates to be considered as members of a
MRPA clone, a threshold of 95% or greater similarity (by the similarity matrix) was used
for classification as members or non-members. A group of isolates considered to be 95%
similar would indicate that all isolates are at least 95% similar to every other isolate in the
group. The dominant clone was first identified by typing a group of 23 MRPA isolates in
October 2004. The data showed that roughly 50% of the isolates belonged to a single
clone (labeled the dominant clone) exhibiting a highly similar DNA profile. Thorough
analysis of four years of MRPA typing data has revealed that isolates within the dominant
clone group exhibit greater than 95% similarity, and a recent publication also confirmed
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a

b

c

Figure 3. DiversiLab Report Components.
Note: The DiversiLab system provides several visual data interpretations summarizing the DNA typing
data including (a) a dendrogram (b) a scatterplot and (c) a similarity matrix.

the use of the 95% similarity cut-off for rep-PCR analysis of P. aeruginosa (DoleansJordheim et al., 2009). All other clones (referred to as non-dominant clones) are less than
95% similar to the dominant clone group.

Patient Data
The laboratory data generated from patients included in this study spanned the
period when the initial typing data was obtained in October 2004 through typing data
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obtained in January 2009. Original data generation dates pertaining to patient-related
variables, including clinical data, varied based on when the patients were diagnosed and
when data was first entered into Port CF. Data for each variable was obtained from the
patient’s Port CF record and recorded as text in a Microsoft Excel spreadsheet.
Categorical variables were coded as described in the Variables section. Once all
applicable data was collected for a patient from Port CF, the patient’s information was
given an anonymous identifier for the remainder of the study, including all data analysis.
Data Analysis
The data collected for this study was analyzed using SPSS Statistics 17.0 (SPSS
Inc., Chicago, IL). All data, including patient-related variables from Port CF and clone
designations generated by DNA typing, were transferred from a Microsoft Excel
spreadsheet into SPSS by the primary researcher.
The first research question addressed whether a significant relationship existed
between infection with the dominant MRPA clone and patient-related variables prior to
MRPA infection. The research hypothesis was that certain characteristics of patients with
CF predict whether or not they will be infected with the dominant MRPA clone. The
independent variables were multiple patient-related variables including both categorical
and quantitative variables. The categorical independent variables include the following:
age at time of CF diagnosis (before or after age one), CF genotypes or mutations,
mother’s education level, gender, days from clinic visit to MRPA infection diagnosis
(categorized as < 60 days, 61-120 days, or > 120 days), tobramycin use, culture result,
and days from hospitalization to MRPA infection diagnosis (categorized as < 90 days,
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91-180 days, 181-365 days, or > 365 days). The quantitative independent variables
included the following: age at time of MRPA infection diagnosis, body mass index
(BMI), FEV1, and hospitalization length in the year prior to MRPA diagnosis. The
categorical dependent variable was simply the clone infecting that patient, either the
dominant MRPA clone or a non-dominant clone. Descriptive statistics were calculated
for patients in each clonal group (dominant MRPA clone or non-dominant clone) and
included means and medians of quantitative variables for each group as well as
distributions for each categorical variable by group. Logistic regression was performed,
and a p-value of 0.05 (95% confidence) was considered significant. The Hosmer and
Lemeshow goodness-of-fit test was assessed to determine if the model adequately fit the
data, resulting in a non-significant p-value (p > 0.05). The significance (p < 0.05) of the
Omnibus test of model coefficients was evaluated to determine if there was overall model
significance resulting in at least one significant predictor. Logistic regression provided
information (odds ratios) on how much influence each of the predictors (categorical and
quantitative independent variables) had on whether the patient became infected by the
dominant MRPA clone or a non-dominant clone. The analysis also determined which of
the predictors were statistically significant and not due to chance.
The second research question addressed whether infection with the dominant
MRPA clone was related to patient outcome. The research hypothesis was that infection
with the dominant MRPA clone affects patient outcome. The independent variable was
the clone infecting that patient, either the dominant MRPA clone or a non-dominant
MRPA clone. The dependent variables for the first patient outcome analysis were
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quantitative patient outcome data including change in FEV1 per month, change in body
mass index per month, and hospitalization days per year. The second analysis evaluated
long-term patient outcomes including change in FEV1 per year, change in body mass
index per year, and hospitalization days per year. Descriptive statistics were calculated
for patient outcomes in each clonal group (dominant MRPA clone or non-dominant
clone) and included means and medians of quantitative variables for each group as well
as distributions for each categorical variable by group. MANOVA was performed for
both the short-term and long-term quantitative patient outcome variables, and a p-value
of 0.05 (95% confidence) was considered significant. Several additional tests were run in
parallel with the analysis including Box’s test, for which a non-significant result upholds
the assumption of homoscedasticity of the data, Wilks’ lambda, which determines overall
model significance (p < 0.05), and Levene’s test, for which non-significance confirms the
assumption of equal group error variances. MANOVA evaluated whether a significant
difference existed between the two clonal groups, the dominant clone and the nondominant clone. Finally, patient mortality was assessed by conducting a Kaplan-Meier
Survival Analysis.
Limitations
A major limiting factor of this study was the sample size. The study was limited
first by the number of patients with cystic fibrosis treated by the CF Center, and secondly
by the number of patients with CF that became infected with MRPA. Limiting the study
to only one CF care center added the risk that the dominant clone may have been specific
to this one center. The study was also limited by the performance of clinically validated
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laboratory assays used to analyze patient samples, specifically due to the prolonged
period of clinical evaluation and laboratory testing for this study. Other limitations
included possible heterogeneity in terms of clinical evaluation by multiple health care
providers (even though the study was based in one center). Individual patients may have
been evaluated by different providers during the course of the study (e.g. different
respiratory therapists for FEV1 measurements).
In addition, P. aeruginosa isolates may not have been successfully cultured by the
laboratory if specimen transport was delayed or compromised in some way. Possible
MRPA isolates could have been missed in the clinical microbiology laboratory. MRPA
strains may have also mutated or evolved during natural history of the pathogen resulting
in altered chromosomal profiles. Finally, only a limited number of bacterial colonies were
evaluated so it is possible that the presence of MRPA may have been missed due to
colony sampling in the clinical microbiology laboratory.
Patient-related variables and patient outcomes were compared against clone
designation to determine which variables exhibited significant relationships. By
combining the vast amount of patient data available in Port CF with the molecular typing
results, identification of potential risk factors for acquisition of the dominant MRPA
clone and implications for patient outcomes once infection with the dominant clone has
been confirmed were obtained. Based on potential significant relationships, future
prevention and treatment strategies as well as larger studies could be devised.

CHAPTER 4: RESULTS

The study was intended to evaluate the utility of molecular typing in multiplyresistant Pseudomonas aeruginosa (MRPA) infections in pediatric patients with cystic
fibrosis (CF). The study was designed to retrospectively analyze the relationships
between MRPA clone (dominant or non-dominant clone) and patient characteristics,
including demographic information, clinical parameters, and patient outcome data in
order to determine potential risk factors for acquisition of the dominant MRPA clone and
subsequent differences in patient outcome between the two clonal groups.
The following chapter will include a description of the data obtained through the
course of the study. Details of the sample set and data preparation will be discussed.
Statistical analyses, including logistic regression for potential risk factors related to
infection with the dominant MRPA clone and MANOVA for differences between the two
clonal groups, will be presented as well as findings related to patient mortality,
hospitalization, and statistical power.
Sample Set
Institutional Review Board (IRB) approval was obtained from Baylor College of
Medicine (BCM) and Virginia Commonwealth University (VCU). Study participants
were pediatric patients of the CF Care Center at Texas Children’s Hospital (TCH)/BCM
between 2004 and 2009. All patients had a previously confirmed MRPA infection, and
77
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the MRPA isolates had been submitted for molecular typing by the Molecular
Microbiology laboratory at TCH. In addition, all patients in the study sample had
previously consented to inclusion of their data in the BCM module of the national patient
registry maintained by the CF Foundation (Port CF). A total of 71 patients of the 82
patients evaluated met the inclusion criteria for the study.
Eleven patients for which molecular typing data of MRPA infection was available
were excluded from the study. These patients were seen at the TCH/BCM CF Care
Center for transplant evaluation. All the excluded patients have a confirmed diagnosis of
CF and MRPA infection, but as they are visiting patients, their records are maintained by
their original CF Care Center. Because consent for this study was based on consent to the
BCM module of Port CF, data for these individuals could not be obtained.
Missing Data
In the entire data set, only two individual data points were missing. Both data
points involved FEV1 measurements for the same patient. The patient was too young (5
years old at the time of MRPA infection) to perform accurate lung function testing, so no
data was available for FEV1 measurements surrounding the time of MRPA infection.
Because both data points involved a single patient, this patient was omitted from
statistical analyses requiring data for FEV1, yielding a final sample size of 70 for analyses
involving lung function.
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Data Preparation
Data Collection
Molecular typing data was obtained from the Molecular Microbiology laboratory
at TCH, and clone designation was performed as described in the following section. Data
pertaining to patient-related variables and patient outcome variables were obtained
through Port CF. Each patient record was reviewed in Port CF to obtain demographic
information as well as specifics of the original diagnosis (such as age of diagnosis and CF
genotype). In addition, the clinic and hospital visits surrounding diagnosis with MRPA
were identified, and relevant data was extracted from the records of those visits. Figure 4
displays the timeline for original collection of the data. All relevant patient data was
recorded in a Microsoft Excel spreadsheet. Once all necessary data had been captured,
each patient was assigned an anonymous identifier (numbered 1-71) and all patient
identifiers were removed from the data sheet.
Coding of Data
Once the data set was anonymized, each categorical variable was coded and
calculations for quantitative variables, such as changes in lung function or nutritional
status and annual hospitalization rates, were performed as described previously.
Clone Designation
Patients were designated as members of the dominant clone or the non-dominant
clone group based on previous MRPA molecular typing results generated by the
Molecular Microbiology laboratory at Texas Children’s Hospital. A separate report was
created depicting only the 71 patients included in the study and removing all patient
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Figure 4. Timeline of Data Collection for Study Participants.

identifiers. Based on the previously described 95% similarity cutoff for group
determination, 32 patients (45%) were found to be members of the dominant clone group
and the remaining 39 patients (55%) were deemed members of the non-dominant clone
group. The molecular profiles and dendrogram are displayed in Figure 5, with the
dominant clone group identified by the red box. Similarly, the dominant clone group is
highlighted by a red circle in the scatterplot representation in Figure 6. In both graphical
depictions of similarity, it is evident that patient 32 (report key number 35) is highly
similar to the dominant clone group. However, this patient is below the 95% similarity
cutoff as illustrated in the dendrogram, and therefore, was determined to be a member of
the non-dominant clone group.
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95% Similarity

Key

Pt ID

Dominant Clone

Figure 5. Molecular Typing
Report Dendrogram.
Note: The similarity of each molecular
profile is displayed in a tree-wise
hierarchy. Each patient in the report
data set is assigned a key number by the
online report generator, and the “Pt ID”
column represents the anonymous
identifier assigned to each patient for
the study. The blue line delineates the
95% similarity cutoff, and the red box
identifies the dominant clone group.
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Dominant Clone

Figure 6. Molecular Typing Report Scatterplot.
Note: The scatterplot representation depicts the relatedness of each molecular profile in the data set. The
dominant clone is highlighted by the red circle in the center of the scatterplot grouping.

Statistical Analysis
Patient-related Variables as Risk Factors for Dominant Clone Acquisition
The first question addressed by the study was whether a significant relationship
existed between patient-related variables prior to infection and the subsequent clone the
patient contracted. Categorical and quantitative variables, as described in Table 2, were
selected for analysis. The proposed hypothesis is as follows:
HO1: Patient-related variables prior to MRPA infection are correlated to infection with
the dominant MRPA clone.
Descriptive Statistics
Categorical variables. The distribution of all categorical variables included in the
analysis of patient-related variables as potential risk factors for dominant MRPA clone
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infection is displayed in Tables 4 and 5. Compared to the percentages noted in the overall
sample population, there were no noticeable differences in either the dominant or nondominant clone group in regards to demographic-based variables (gender, age at CF
diagnosis, CFTR genotype, and mother’s educational level). A similar pattern was seen in
the categorical variables related to the time of MRPA infection diagnosis. A slight
increase in the number of patients hospitalized less than 90 days prior to MRPA infection
diagnosis was noted in the dominant clone group (43.75%) as compared to the nondominant clone group (25.64%).
Table 4.
Distribution of Demographic Categorical Variables
Variable Category

Total sample
N = 71

Dominant clone
N = 32

Non-dominant clone
N = 39

41 (57.75%)
30 (42.25%)

20 (62.50%)
12 (37.50%)

21 (53.85%)
18 (46.15%)

54 (76.06%)
17 (23.94%)

24 (75.00%)
8 (25.00%)

30 (76.92%)
9 (23.08%)

42 (59.15%)
19 (26.76%)
10 (14.08%)

18 (56.25%)
9 (28.13%)
5 (15.63%)

24 (61.54%)
10 (25.64%)
5 (12.82%)

10 (14.08%)
28 (39.44%)
10 (14.08%)
14 (19.72%)
9 (12.68%)

4 (12.50%)
14 (43.75%)
6 (18.75%)
4 (12.50%)
4 (12.50%)

6 (15.38%)
14 (35.90%)
4 (10.26%)
10 (25.64%)
5 (12.82%)

Gender
Male
Female
Age at CF diagnosis
< Age 1
> Age 1
CFTR genotype
delF508/delF508
delF508/other
Other
Mother’s educational level
Less than HS
High school/GED
Some college
College graduate
Unknown

Quantitative variables. The means and medians for each of the patient-related
quantitative variables included in the analysis of risk factors for dominant MRPA clone
acquisition are listed in Table 6. No noticeable difference was observed in age at the time
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Table 5.
Distribution of Categorical Variables Prior to MRPA Infection Diagnosis

Variable

Category

Total sample
N = 71

Days from clinic visit to MRPA infection
< 60 days
23 (32.39%)
61-120 days
33 (46.48%)
> 120 days
15 (21.13%)
Days from hospitalization to MRPA infection
< 90 days
24 (33.80%)
91-180 days
16 (22.54%)
181-365 days
6 (8.45%)
> 365 days
25 (35.21%)
Tobramycin use
No
47 (66.20%)
Yes
24 (33.80%)
Culture result
No organisms
5 (7.04%)
P. aeruginosa (PA)
23 (32.39%)
PA + MSSA
11 (15.49%)
PA + MRSA
11 (15.49%)
PA + other
13 (18.31%)
Other organism(s)
8 (11.27%)

Dominant
clone
N = 32

Non-dominant
clone
N = 39

11 (34.38%)
13 (40.63%)
8 (25.00%)

12 (30.77%)
20 (51.28%)
7 (17.95%)

14 (43.75%)
9 (28.13%)
1 (3.13%)
8 (25.00%)

10 (25.64%)
7 (17.95%)
5 (12.82%)
17 (43.59%)

23 (71.88%)
9 (28.13%)

24 (61.54%)
15 (38.46%)

2 (6.25%)
10 (31.25%)
4 (12.50%)
5 (15.63%)
6 (18.75%)
5 (15.63%)

3 (7.69%)
13 (33.33%)
7 (17.95%)
6 (15.38%)
7 (17.95%)
3 (7.69%)

of MRPA infection diagnosis or in BMI or FEV1 just prior to MRPA infection diagnosis.
A difference was realized in the number of days hospitalized in the year prior to MRPA
infection diagnosis between patients in the dominant clone (mean = 26.53 days) and the
non-dominant clone (mean = 15.21 days).
Logistic Regression
To determine if a significant relationship exists between clonal group (dominant
or non-dominant) and several categorical and quantitative patient-related variables,
logistic regression was employed using SPSS Statistics 17.0. Logistic regression is an
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Table 6.
Means and Medians of Quantitative Patient-related Variables
Total sample Dominant clone Non-dominant clone
N = 71
N = 32
N = 39
Age at MRPA infection diagnosis (in years)
Mean
14.30
14.22
14.36
Median
15.00
15.00
15.00
BMI prior to MRPA infection diagnosis (percentile)
Mean
37.45
37.60
37.33
Median
25.39
19.53
30.83
FEV1 prior to MRPA infection diagnosis (percentile)
Mean
68.50
67.57
69.29
Median
79.54
67.99
73.71
Days hospitalized in the year prior to MRPA infection diagnosis
Mean
20.31
26.53
15.21
Median
15.00
19.50
4.00
Variable

evaluation of the probability of group membership based on a set of predictor variables
(Tabachnick & Fidell, 2001). All 12 patient-related variables were entered into the
logistic regression model, and then subsets of the patient-related variables pertaining to
patient demographics, data collected at the time of MRPA infection, variables related to
the chronology of MRPA infection, and variables related to the disease state at the time
of MRPA infection were also tested by logistic regression.
The first model included all patient-related variables for the analysis of risk
factors of infection with the dominant MRPA clone. The Omnibus tests of model
coefficients did not indicate overall model significance (p = 0.720). The Hosmer and
Lemeshow test did show that the model adequately fit the data (p = 0.367). Significance
and odds ratios for each predictor included in the model of all twelve patient-related
variables are listed in Table 7.
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Table 7.
Logistic Regression Output for All Patient-related Variables
Predictor
Gender
Age at CF diagnosis
CFTR genotype (delF508/delF508)
delF508/other
Other
Mother’s education level (less than high school)
High school/GED
Some college
College graduate
Unknown
Age at MRPA infection diagnosis
Days from clinic visit to MRPA infection (< 60 days)
61-120 days
>120 days
Days from hospitalization to MRPA infection
(>365 days)
< 90 days
91-180 days
181-365 days
BMI prior to MRPA infection
FEV1 prior to MRPA infection
Tobramycin use
Culture results prior to MRPA infection
(no organisms)
P. aeruginosa (PA)
PA + MSSA
PA + MRSA
PA + Other organism
Other organism(s)
Days hospitalized in the year prior to MRPA
infection

Odds
ratio
2.038
1.493

0.553-7.505
0.355-6.285

0.706
0.908

0.088-5.686
0.105-7.866

0.671
2.028
3.895
0.584
0.992

0.049-9.166
0.255-16.131
0.233-65.223
0.055-6.221
0.830-1.186

0.751
0.350

0.102-5.556
0.052-2.349

0.364
0.105
0.343
0.909
0.967
0.761
0.681

2.912
4.798
0.234
1.002
1.001
1.270

0.290-29.277
0.722-31.879
0.012-4.720
0.976-1.028
0.968-1.035
0.272-5.918

0.981
0.628
0.178
0.525
0.906
0.453

1.043
0.579
0.192
0.444
1.165
1.015

0.034-32.412
0.064-5.258
0.017-2.114
0.036-5.446
0.093-14.668
0.976-1.056

p
0.284
0.585
0.928
0.744
0.930
0.473
0.765
0.504
0.344
0.656
0.929
0.473
0.779
0.280
0.184

95% C.I.

The second model included only the patient-related variables considered
demographic information, specifically age at time of CF diagnosis, CFTR genotype,
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mother’s educational level, and gender. Again, the model was not found to be significant
(p = 0.846), and odds ratios were all below 2.0. Results are listed in Table 8.
Table 8.
Logistic Regression Output for Demographic Variables
Predictor
Gender
Age at CF diagnosis
CFTR genotype (delF508/delF508)
delF508/other
Other
Mother’s education level (less than high school)
High school/GED
Some college
College graduate
Unknown

p
0.487
0.864
0.725
0.433
0.643
0.543
0.717
0.881
0.503
0.358

Odds ratio
1.423
0.904

95% C.I.
0.618-3.273
0.342-2.391

0.540
0.669

0.148-1.966
0.160-2.792

0.701
1.127
1.884
0.422

0.140-3.522
0.304-4.173
0.398-8.924
0.090-1.979

The third model tested by logistic regression included all patient-related variables
relevant to the time of MRPA infection (age at time of MRPA infection diagnosis, days
from clinic visit to MRPA infection, days from hospitalization to MRPA infection, BMI
prior to MRPA infection, FEV1 prior to MRPA infection, tobramycin use, culture results,
and days hospitalized in the year prior to MRPA infection). The model was further
divided into two subsets related to chronology of infection (age at time of MRPA
infection diagnosis, days from clinic visit to MRPA infection, days from hospitalization
to MRPA infection) and disease state (BMI prior to MRPA infection, FEV1 prior to
MRPA infection, tobramycin use, culture results, and days hospitalized in the year prior
to MRPA infection).
The model including all patient-related variables at the time just prior to MRPA
infection (results shown in Table 9) was non-significant (p = 0.626), but the odds ratio

88
Table 9.
Logistic Regression Output for Variables Related to the Time Just Prior to MRPA
Infection Diagnosis
Predictor
Age at MRPA infection diagnosis
Days from clinic visit to MRPA infection (< 60 days)
61-120 days
>120 days
Days from hospitalization to MRPA infection
(>365 days)
< 90 days
91-180 days
181-365 days
BMI prior to MRPA infection
FEV1 prior to MRPA infection
Tobramycin use
Culture results prior to MRPA infection
(no organisms)
P. aeruginosa (PA)
PA + MSSA
PA + MRSA
PA + Other organism
Other organism(s)
Days hospitalized in the year prior to MRPA
infection

Odds
ratio
0.967

0.836-1.119

1.041
0.466

0.175-6.204
0.099-2.195

0.128
0.075
0.437
0.987
0.912
0.467
0.743

4.595
4.880
0.328
1.000
1.002
1.637

0.644-32.769
0.851-27.993
0.020-5.456
0.976-1.025
0.972-1.033
0.434-6.174

0.985
0.434
0.255
0.409
0.966
0.959

1.028
0.447
0.281
0.400
1.051
1.001

0.053-19.967
0.060-3.360
0.032-2.494
0.045-3.529
0.110-10.024
0.970-1.032

p
0.653
0.456
0.965
0.334
0.135

95% C.I.

values related to days from hospitalization to MRPA infection were note-worthy. With a
reference category of no hospitalization in the year prior to MRPA infection diagnosis,
patients who were hospitalized less than 90 days prior to MRPA infection diagnosis were
4.595 times (p = 0.128) more likely to be infected with the dominant clone than a nondominant clone. Similarly, patients who were hospitalized 91-180 days prior to MRPA
infection diagnosis were 4.88 times (p = 0.075) more likely to be infected with the
dominant clone.
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Looking more closely at those patient-related variables that were specific to
chronology of the MRPA infection (Table 10), the model was non-significant at a p-value
of 0.184 but confirmed the findings in relation to hospitalization prior to MRPA
infection. The one significant predictor of infection with the dominant MRPA clone
versus a non-dominant MRPA clone was hospitalization less than 90 days prior to MRPA
infection diagnosis (p = 0.035), where infection with the dominant clone was 4.019 times
more likely than infection with a non-dominant clone. Patients hospitalized 91-180 days
prior to infection were 2.960 times more likely to belong to the dominant clone group (p
= 0.113).
Table 10.
Logistic Regression Output for Variables Related to Chronology of MRPA Infection
Predictor
Age at MRPA infection diagnosis
Days from clinic visit to MRPA infection
(< 60 days)
61-120 days
>120 days
Days from hospitalization to MRPA infection
(>365 days)
< 90 days
91-180 days
181-365 days

Odds
ratio
0.974

0.859-1.104

0.490
0.149
0.076

0.596
0.361

0.137-2.588
0.091-1.439

0.035
0.113
0.509

4.019
2.960
0.453

1.100-14.677
0.775-11.314
0.043-4.755

p
0.678
0.329

95% C.I.

Because of the significance of recent hospitalization, patients were then divided
into two groups based on hospitalization < 180 days prior to MRPA infection diagnosis
and > 180 days prior to MRPA infection diagnosis. A chi-square analysis to determine if
the observed frequencies were significantly different than the expected frequencies was
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performed based on clonal group. The results were statistically significant with a p-value
of 0.017.
The subset specific to disease state at the time of MRPA infection (Table 11) was
non-significant (p = 0.731). The number of days hospitalized in the year prior to MRPA
infection was the closest to significant (p = 0.074) and is most likely related to the
significance of the proximity of hospitalization to MRPA infection with the dominant
clone (as compared to no hospitalization in the year prior to infection).
Table 11.
Logistic Regression Output for Variables Related to Disease State Prior to MRPA
Infection
Predictor

p

BMI prior to MRPA infection
FEV1 prior to MRPA infection
Tobramycin use
Culture results prior to MRPA infection
(no organisms)
P. aeruginosa (PA)
PA + MSSA
PA + MRSA
PA + Other organism
Other organism(s)
Days hospitalized in the year prior to MRPA
infection

0.951
0.723
0.473
0.890
0.769
0.280
0.295
0.362
0.527
0.074

Odds
ratio
0.999
1.005
1.501

0.978-1.021
0.977-1.033
0.494-4.561

0.662
0.364
0.339
0.397
0.521
1.024

0.042-10.360
0.058-2.277
0.045-2.564
0.055-2.895
0.069-3.933
0.998-1.052

95% C.I.

Differences in Patient Outcome Based on MRPA Clone
The second question posed by the study was whether infection with the dominant
clone affected patient outcome. The specific quantitative patient outcome variables
enlisted for this analysis included short-term changes in BMI and FEV1, long-term
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changes in BMI and FEV1, and days hospitalized per year. Patient mortality was also
evaluated separately as an outcome. The proposed hypothesis was:
HO2: Infection with the dominant MRPA clone is correlated to patient outcome.
Descriptive Statistics
The mean and median of each of the quantitative patient outcome variables are
listed in Table 12. Only minimal differences were noted in changes per month of BMI
and FEV1 percentile, but noticeable differences were seen in the extended time span
employed to generate changes per year of BMI and FEV1 percentile. In addition, patients
infected with the dominant MRPA clone (mean = 39.42 days, median = 29.59 days) spent
almost 14 more days per year in the hospital than patients infected with a non-dominant
clone (mean = 25.78 days, median = 14.81 days). With regard to extended outcomes,
patients were followed for a mean of 3.07 years (range = 0.61-6.87 years), with slightly
longer follow-up for the dominant clone group (mean = 3.58 years) versus the nondominant clone group (mean = 2.65 years).
MANOVA
Multivariate analysis of variance was performed to determine if a significant
difference existed between the means of quantitative short-term and long-term patient
outcomes for the dominant clone and the non-dominant clone. MANOVA tests whether
the group mean differences between a set of quantitative dependent variables are likely to
have occurred by chance (Tabachnick & Fidell, 2001). Box’s test of equality of
covariance upheld the assumption of homoscedasticity (p = 0.096 for short-term and p =
0 for long-term), and Levene’s test of equality of error variances confirmed the
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Table 12.
Means and Medians of Quantitative Patient Outcome Variables
Total sample Dominant clone Non-dominant clone
N = 71
N = 32
N = 39
Change in BMI per month following MRPA infection (percentile)
Mean
-0.04
-0.27
0.16
Median
-0.11
0.11
-0.12
Change in BMI per year following MRPA infection (percentile)
Mean
-1.64
-3.73
0.12
Median
-0.51
-0.60
-0.38
Change in FEV1 per month following MRPA infection (percentile)
Mean
0.33
0.88
-0.12
Median
0.13
0.72
-0.10
Change in FEV1 per year following MRPA infection (percentile)
Mean
-2.10
-3.70
-0.75
Median
-1.92
-2.50
-0.73
Days hospitalized per year following MRPA infection
Mean
31.92
39.42
25.78
Median
22.85
29.59
14.81
Variable

assumption of equal group error variances (p-values ranged from 0.307-0.537). Wilks’
Lambda did not determine that the overall model of differences between the two clonal
groups was significant (p = 0.337 for short-term and p = 0.212 for long-term). Statistics
for each individual variable are listed in Table 13.
Table 13.
MANOVA Results for Differences in Patient Outcome
Outcome
Change in BMI/month
Change in BMI/year
Change in FEV1/month
Change in FEV1/year
Days hospitalized

F
0.368
2.473
1.404
2.183
2.073

p
0.546
0.120
0.240
0.144
0.155

Partial eta squared
0.005
0.350
0.020
0.310
0.030

Observed power
0.092
0.341
0.215
0.308
0.295
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Mortality
In the complete data set of 71 patients, only 10 patients died during the course of
the study. Patient outcome data was available for a variable length of time due to the
design of the study (ranging from three months to six years). Four patients in the nondominant clone group (10.26%) and six patients in the dominant clone group (18.75%)
died. The length of time between MRPA infection diagnosis and death for each patient is
listed in Table 14. While the average time to death for the non-dominant clone group
(mean = 451 days) was nearly half of that of the dominant clone group (mean = 1062
days), the number of patients who died was too small to determine significance or
perform any further analysis.
Table 14.
Patient Mortality by Clonal Group
Clone
Non-dominant clone

Patient ID

Time to death

18
28
32
49

99 days
456 days
448 days
800 days

Dominant clone

Average
451 days

1062 days
14
19
23
37
50
53

380 days
1909 days
1457 days
1540 days
763 days
321 days

Kaplan-Meier survival analysis was also performed using SPSS Statistics 17.0.
The analysis compared the survival rates based on the number of days following MRPA
infection diagnosis that follow-up information was available. The number of days varied
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depending on when the patient was originally diagnosed with MRPA infection, how long
the patient was treated at the specific CF Care center following diagnosis with MRPA,
and when the patient died. Survival rates were compared between the dominant clone
group and the non-dominant clone group, and the resulting graph is shown in Figure 7.
Small vertical lines indicate the last date of follow-up for patients that were alive at the
end of the study, and each step-down in the graph indicates a death in the clone group.
Survival rates are based on the number of patients in that clone group that were still being
monitored at that length of time. Survival was not found to be significant among groups
with a p-value of 0.743.
Chronological Analysis of Diagnosis and Hospitalization
MRPA Infection Diagnosis Date
The clustering of the diagnoses of MRPA infections in the sample set provided
additional perspective. Figure 8 depicts the date of diagnosis of MRPA infection for
every patient in the dataset, with the time from infection to death noted for the 10 patients
in the sample set that died. Clusters of MRPA infection diagnosis are evident in early
2004, mid-2005, and late 2006. Interestingly, 75% of new MRPA cases beyond mid-2007
were in the non-dominant clone group. Infection with the dominant MRPA clone as
opposed to a non-dominant MRPA clone declined through the timeframe of the study
with an incidence of 56% from 2003-2004, 47% from 2005-2006, and 36% from 20072008. This finding suggests that the mode of transmission may have been controlled or
slowed in some way. However, an additional cluster of the dominant MRPA clone was
present in late August 2008, with three patients diagnosed within 20 days of each other.
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Figure 7. Kaplan-Meier Survival Analysis.
Note: The graph displays the estimated survival rate (in number of days following MRPA infection)
between the dominant MRPA clone group and the non-dominant MRPA clone group.

Hospitalization Overlap
The significance of recent hospitalization prior to MRPA infection in the
dominant clone group led to a more detailed evaluation of inpatient episodes in the
dominant clone group. Based on the hospitalization episode chart in Figure 9, the
clustering of patients’ in-hospital encounters is evident. The green triangles represent the
dominant MRPA clone, and the overlap in patients with that clone can been seen in late
2003 and early to mid-2005.
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Figure 8. Timeline of MRPA Infection.
Note: MRPA Infection diagnosis dates are noted chronologically by clone, and the extended lines represent
time to death for the 10 patients in the data set that died. The y-axis is the anonymized patient identifier,
and the x-axis represents the date of MRPA infection diagnosis. Blue squares indicate patients in the nondominant MRPA clone group and green triangles represent patients in the dominant MRPA clone group.
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Figure 9. Hospitalization in the Year Prior to MRPA Infection.
Note: The graph displays dates of the hospitalization episode just prior to diagnosis with MRPA infection
for each patient in the dominant and non-dominant clone group. The length of the hospital stay is also
displayed. The y-axis is the anonymized patient identifier, and the x-axis represents the date of
hospitalization just prior to MRPA infection diagnosis. Blue squares and green triangles denote the hospital
stay just prior to MRPA infection diagnosis for patients in the non-dominant and dominant MRPA clonal
groups respectively.

Taking the analysis one step further, the following figures display all
hospitalization episodes, both pre and post-MRPA infection diagnosis, for patients in the
dominant clone group. Significant overlap of confirmed dominant MRPA clone patients
with pre-MRPA hospitalization episodes was observed. The graphs are divided into twoyear intervals to more easily depict the overlap with the pre-MRPA episodes. From 20032004 (Figure 10), five patients with no confirmed diagnosis of MRPA were hospitalized
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Figure 10. Hospitalization Overlap in the Dominant Clone 2003-2004.
Note: Overlap of inpatient stays for patients in the dominant clone group is compared between the
hospitalization episode just prior to MRPA infection (red circles) and all post-MRPA infection diagnosis
hospitalization episodes (green triangles) from January 2003 through December 2004. The y-axis is the
anonymized patient identifier, and the x-axis represents the date of hospitalization.

simultaneously with patients infected with the dominant MRPA clone and later were
diagnosed with the same dominant clone. A total of 21 of the 32 patients (65%) in the
dominant MRPA clone had documented simultaneous inpatient hospital stays with
previously infected dominant clone patients with ten patients in 2005-2006 (Figure 11)
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Figure 11. Hospitalization Overlap in the Dominant Clone 2005-2006.
Note: Overlap of inpatient stays for patients in the dominant clone group is compared between the
hospitalization episode just prior to MRPA infection (red circles) and all post-MRPA infection diagnosis
hospitalization episodes (green triangles) from January 2005 through December 2006. The y-axis is the
anonymized patient identifier, and the x-axis represents the date of hospitalization.

and six patients in 2007-2008 (Figure 12) experiencing the same situation. The increased
hospitalization rate of patients in the dominant MRPA clone group actually increased the
likelihood of exposure to the clone during inpatient episodes for patients with CF.
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Figure 12. Hospitalization Overlap in the Dominant Clone 2007-2008.
Note: Overlap of inpatient stays for patients in the dominant clone group is compared between the
hospitalization episode just prior to MRPA infection (red circles) and all post-MRPA infection diagnosis
hospitalization episodes (green triangles) from January 2007 through October 2008. The y-axis is the
anonymized patient identifier, and the x-axis represents the date of hospitalization.

A final interesting situation regarding hospitalization is the amount of time from
initial respiratory sample collection to culture result. Respiratory cultures are generally
obtained upon admission, but it can be several days before final results, especially
antibiotic susceptibilities, are available. For nine patients in the dominant MRPA clone
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group, the diagnosis of MRPA was made during an inpatient encounter. This means that
upon admission, the patient was classified as not having MRPA. However, upon
admission, they were in fact infected with the dominant MRPA clone as evidenced but
the culture results obtained days later. Prior to September 2005, these patients would not
have been treated with additional precautions, such as isolation, because their records did
not indicate infection with multiply-resistant P. aeruginosa. Therefore, the dominant
clone could have been spread throughout the inpatient area even though all standard
practices were followed. In September 2005, new infection control practices were
adopted in the Pulmonology unit that required all patients be placed under contact
isolation until final respiratory culture results confirmed the absence of infections
requiring contact isolation. Figure 13 plots the inpatient episodes for the nine patients that
were diagnosed with the dominant MRPA clone during hospitalization, six of which were
prior to September 2005. Based on this plot, it is possible that as many as five uninfected
patients, who later were diagnosed with the dominant clone, may have come into contact
with a patient with an undiagnosed dominant MRPA clone infection. Figure 14 depicts
the layout of the inpatient area assigned to care for patients with CF. The proximity of the
patient rooms as well as central areas for treatment, pulmonary function testing, and
patient transport further emphasizes the possibility of inpatient transmission of MRPA
between patients with CF.
For comparison, overlap of inpatient stays in the non-dominant clone group was
also evaluated. Of the 39 patients infected by a non-dominant MRPA clone, only 14
(36%) exhibited an overlap in hospitalization prior to MRPA infection diagnosis with a
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Figure 13. Hospitalization Overlap with Undiagnosed Dominant MRPA Clone.
Note: The overlap between pre-MRPA diagnosis hospital encounters and undiagnosed MRPA inpatient
encounters (MRPA diagnosed from the respiratory culture obtained at time of hospital admission) is
displayed for the entire study timeframe. The y-axis is the anonymized patient identifier, and the x-axis
represents the date of hospitalization. The undiagnosed MRPA instances are marked by a purple diamond
while the hospital visits just prior to MRPA infection diagnosis for patients in the dominant clone are
shown by red circles. The implementation of contact isolation upon admission in September 2005 is noted
by the vertical line.

patient known to be infected with the dominant MRPA clone. This is in contrast to the
65% of patients in the dominant MRPA clone group that had pre-MRPA infection
hospitalization episodes coinciding with a confirmed dominant MRPA clone patient.
Further analysis evaluated the undiagnosed MRPA during hospitalization factor in the
non-dominant clone group. While a total of 10 patients in the non-dominant clone group
were diagnosed with a MRPA infection based on their respiratory culture at time of
hospital admission (thus not requiring infection control practices specific to MRPA
during the first few days of the inpatient episode), no patients in the non-dominant clone
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Figure 14. Inpatient Areas Assigned to Patients with CF.
Note: The diagram highlights all patient care areas in pink and hospital staff and family areas in blue.
Elevator bays are displayed by the standard “x” marking.

group experienced a coinciding hospitalization prior to MRPA diagnosis before
September 2005. This finding, displayed in Figure 15, further highlights the lack of
simultaneous hospitalization in the non-dominant MRPA clone group as compared to the
dominant MRPA clone group. Also noteworthy in Figure 15 are the coinciding hospital
stays of Patients 61 (post-infection hospital stay of a known non-dominant MRPA
patient) and 70 (a pre-MRPA hospital stay). The molecular profiles for these two nondominant MRPA clone patients were unique, with a similarity of only 69.8%.
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Figure 15. Hospitalization Overlap with Undiagnosed Non-Dominant MRPA Clones.
Note: Several instances of MRPA diagnosis from respiratory culture obtained upon hospital admission
were present in the non-dominant clone group, represented by purple diamonds, but no overlap was seen
with hospital visits just prior to MRPA diagnosis in the non-dominant clone group (red circles). The y-axis
is the anonymized patient identifier, and the x-axis represents the date of hospitalization. The
implementation of contact isolation upon admission in September 2005 is noted by the vertical line.

Power Analysis
The most significant limiting factor of this study was the limited sample size.
Because the study was restricted to one CF care center, only 71 patients were eligible for
the study. The small sample set increases the risk of a Type II error, failing to find a
significant relationship when one exists (Polit & Beck, 2004). Power was estimated using
nQuery Advisor 7.0 (Statistical Solutions, Saugus, MA) for the identification of risk
factors for dominant MRPA clone infection and SPSS Statistics 17.0 (SPSS Inc.,
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Chicago, IL) for the analysis of differences between the two clonal groups. Power
projections from nQuery Advisor 7.0 assume a normal distribution of variables and were
calculated using the resulting R2 from the logistic regression analysis with an alpha level
of 0.05 and a total sample size of 71. Projected power for the overall model for
determination of risk factors for infection with the dominant MRPA clone was calculated
to be 96%. Further division of variables into demographics and clinical parameters at the
time of MRPA infection exhibited an estimated power of 42% and 87% respectively.
When analyzing the smaller subsets of variables, the subset related to chronology of
MRPA infection (p = 0.184) was the most statistically relevant and had an estimated
power of 85%. The subset specific to disease state prior to MRPA infection had an
estimated power of 57%. Power output from MANOVA analysis of differences in
patient outcome in SPSS Statistics 17.0 is listed in Table 13. The quantitative patient
outcome variables all had an estimated power below 35%.
Summary
Seventy-one patients with CF infected with MRPA were included in the study.
The first research question was designed to establish if a significant relationship existed
between infection with the dominant MRPA clone and patient-related variables prior to
MRPA infection. The second research question evaluated if infection with the dominant
MRPA clone affected quantitative patient outcome variables. Descriptive statistics were
calculated for all variables, logistic regression was performed for the patient-related
variables, and MANOVA was performed for the patient outcome variables. A survival
analysis was performed to evaluate the significance of patient mortality, and statistical
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power for each analysis was estimated. Hospitalization prior to MRPA infection
diagnosis was found to be a significant factor in subsequent infection with the dominant
MRPA clone. Evidence of overlapping hospitalization episodes was present in a majority
of patients in the dominant MRPA clone group. These findings suggest inpatient stays
were a source of transmission of the endemic MRPA strain in this specific CF population.

CHAPTER 5: DISCUSSION AND CONCLUSION

Multiply-resistant Pseudomonas aeruginosa is a critically important pathogen in
patients with cystic fibrosis in regards to prognosis. The vast majority of patients with CF
acquire P. aeruginosa at some point in their lives, but the antibiotic resistant strains prove
the most difficult to manage and most detrimental to quality of life. The thick mucus
build-up characteristic of patients with CF, due to a defective chloride transport channel,
provides an ideal environment for the proliferation of respiratory pathogens such as P.
aeruginosa. While many antibiotics have been selected to target the infection, P.
aeruginosa eventually develops into a chronic infection due to the adaptation of the
organism into a mucoid phenotype that is difficult if not impossible to eradicate in the
lungs of patients with CF. Compounding the difficulty in treating patients with CF are the
multiply-resistant Pseudomonas aeruginosa strains, organisms that are resistant to all
antibiotics in two of three antibiotics classes (aminoglycosides, fluoroquinolones, and
beta-lactams).
Multiple studies have been published highlighting the utility of molecular typing
to determine relatedness of clones and common sources of transmission. In addition,
many studies have focused on epidemiological surveillance of P. aeruginosa in patients
with CF. Researchers in the United Kingdom and Australia have performed extensive
studies across multiple CF clinics and hospitals and have documented shared P.
107
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aeruginosa clones (D. Armstrong et al., 2003; Scott & Pitt, 2004). Several studies further
evaluated patients with CF infected with an epidemic strain of P. aeruginosa, and the
data showed that those infected with the clone of interest suffered worse clinical
outcomes such as more rapidly declining lung function, poorer nutritional status, and
increased need for hospitalization (Al-Aloul et al., 2004; Edenborough et al., 2004; Nixon
et al., 2001; O'Carroll et al., 2004). However, few studies have focused solely on
identifying risk factors and patient outcomes specifically in MRPA infections in patients
with CF. The results of this study provide insight for the future prevention and treatment
of highly antibiotic resistant P. aeruginosa infections in patients with CF.
Summary of the Study
The CF Center at Texas Children’s Hospital has had a higher than average MRPA
infection rate since the CF Foundation began listing MRPA as a separate pathogen. In
2004, the MRPA infection rate was 25% at TCH and 16.9% nationally. The latest data
available from 2008 shows the infection rate at TCH to be 28% and nationally to be
17.9%. A pilot study was conducted in 2004 that evaluated the use of molecular typing
for determination of relatedness in MRPA clones in patients with CF at TCH. At that
time, a dominant MRPA clone was identified in the patient population. Since 2004,
molecular typing of MRPA isolates has been performed quarterly, and additional patients
have clustered with the dominant clone group.
Data from a total of 71 patients of the TCH CF Care Center were obtained
through the BCM module of Port CF, the national data repository of the CF Foundation.
Molecular typing reports regarding the MRPA isolates of all 71 patients were obtained
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from the Molecular Microbiology laboratory at TCH. Patients were categorized as being
infected with the dominant MRPA clone or with a non-dominant MRPA clone based on
their molecular profiles. Figure 16 describes the workflow of the study including data
collection, analysis, and interpretation.

Figure 16. Workflow of Data Collection and Analysis.
Note: Molecular typing of known MRPA isolates from patients with CF provided the necessary data for
designation of clonal groups. Once retrospective patient data had been collected, statistical analyses such as
logistic regression, MANOVA, and Kaplan-Meier Survival Analysis could be performed. The results then
led to further analysis of hospitalization overlap.
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Discussion of Findings
Risk Factors for Infection with the Dominant MRPA Clone
A review of descriptive statistics for the patient-related variables in Table 2 did
not uncover noticeable differences in demographic factors. While previous studies
suggested these variables may have an impact on acquisition of P. aeruginosa infections
(Demko et al., 1995; Kosorok et al., 1998; McKone et al., 2006; Rodman et al., 2005),
similar distributions were observed between the two groups for gender, age at CF
diagnosis, CFTR genotype, and mother’s educational level. Most other categorical
variables specific to the time just prior to MRPA infection also exhibited no difference in
distribution, specifically days from clinic visit to MRPA, tobramycin use, and culture
result. Days from last hospitalization to MRPA infection did show a noticeable difference
between the two groups, and that finding will be discussed in the following section.
The quantitative patient-related variables also displayed agreement between the
dominant MRPA clone group and the non-dominant MRPA clone group. The mean age
at time of MRPA infection was 14 years for both groups as well as a median of 15 years
for both groups. BMI and FEV1 mean percentiles were within 1% and 2% respectively
between the two groups. A difference was realized in days hospitalized in the year prior
to MRPA infection diagnosis based on membership in the dominant or non-dominant
MRPA clone group.
Logistic regression was performed with five different groups of patient-related
variables. While no overall model was found to be significant, this could be attributed to
the limited sample size available to the study. The only difference between the two
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groups of patients found to be significant was hospitalization less than 90 days prior to
MRPA infection diagnosis (p = 0.035), and the odds ratios for patients hospitalized less
than 90 days and 91-180 days prior to MRPA infection were noteworthy in several of the
analyses.
Hospitalization Prior to MRPA Infection Diagnosis
Several different statistical analyses highlighted the differences in hospitalization
prior to MRPA infection in the two groups. While 43.75% of the patients in the dominant
clone group were hospitalized less than 90 days prior to MRPA infection diagnosis, only
25.64% of patients in the non-dominant clone were hospitalized in that timeframe.
Patients hospitalized within 180 days of MRPA infection diagnosis were more likely to
be infected with the dominant clone than with a non-dominant clone (71.88% versus
43.59%). The model which predicted that hospitalization less than 90 days prior to
MRPA infection was a significant risk factor for acquisition of the dominant MRPA
clone also estimated that patients hospitalized less than 90 days prior to MRPA infection
were four times more likely to acquire the dominant clone rather than a non-dominant
clone. Similarly, patients hospitalized 91-180 days prior to MRPA infection diagnosis
were three times more likely to acquire the dominant MRPA clone.
Further supporting the evidence of hospitalization as a risk factor for acquiring the
dominant MRPA clone was the data regarding hospitalization rate in the year prior to
MRPA infection diagnosis. Patients in the dominant clone group spent an average of 11
more days in the hospital in the year prior to MRPA infection diagnosis compared to
patients in the non-dominant clone group. Figure 9 shows the hospitalization episode just
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prior to MRPA infection diagnosis for each patient in each group. A total of 8 patients in
the dominant clone group and 17 patients in the non-dominant clone group were not
hospitalized in the year prior to MRPA infection and thus are not listed in this chart.
Differences in Patient Outcome Based on MRPA Clone
There was no statistically significant difference between the two clonal groups
based on quantitative patient outcomes: change in BMI, change in FEV1, and annual
hospitalization rate. The patients in the dominant clone group did spend more time in the
hospital with an average of 39.42 days per year (median = 29.59 days) compared to an
average of 25.78 days per year (median = 14.81 days) for the non-dominant clone group.
Although the dominant clone group had a higher hospitalization rate prior to MRPA
infection, they exhibited a post-infection increase in hospitalization rate that was 27%
greater than the non-dominant clone group resulting in almost 14 more days per year in
the hospital for those infected with the dominant MRPA clone. MANOVA found none of
the quantitative patient outcome variables significant, but this analysis was highly
impacted by a low statistical power, which increases the risk of a Type II error.
Short-term differences in BMI and FEV1 were not evident between the two clonal
groups. Overall, there was very little short-term change in BMI or FEV1 for any patients
in the data set. Ninety-two percent of patients exhibited a less than 5% change in BMI
percentile within six months of MRPA infection diagnosis. The case was similar for
short-term FEV1 changes with 86% of patients in the dataset having a less than 5%
change in FEV1 percentile within six months of MRPA infection diagnosis.

113
Extended outcomes began to show a separation between the two groups in terms
of both nutritional status and lung function, with the dominant MRPA clone group
exhibiting poorer outcomes in both areas. Data collected from the last recorded clinic
visit, with a mean follow-up time of three years, showed a 4% decrease per year in both
BMI and FEV1 for patients in the dominant clone group while patients in the nondominant clone group experienced a less than 1% change. BMI changes are difficult to
interpret in this sample set due to the age range (mean age = 14 years), most patients are
experiencing growth spurts so the rates of change in BMI percentile can vary greatly.
However, the fact that both clonal groups had identical mean/median ages makes the
finding of a greater rate of decline in the dominant MRPA clone group more noteworthy.
The Cystic Fibrosis Foundation has also shown a positive association between BMI and
FEV1 percentiles (Patient Registry 2008 Annual Report, 2009; Milla, 2007).
A decrease in lung function of 1-2% per year is expected in patients with CF as
they age, especially during adolescence when the frequency of lung infections increases
(Patient Registry 2008 Annual Report, 2009). Recent studies have also suggested that this
generation of patients with CF may have an even slower rate of decline in FEV1 (Que,
Cullinan, & Geddes, 2006). The increased rate of decline in lung function for patients
infected with the dominant MRPA clone translates into a shorter life expectancy
(Schunemann, Dorn, Grant, Winkelstein, & Trevisan, 2000). The previous studies
documenting decreased lung function in the Liverpool epidemic P. aeruginosa strain and
the Australian epidemic P. aeruginosa strain as compared to non-epidemic strains found
differences in FEV1 decline of -4.4% and -1.3%, respectively, comparable to the
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difference of -2.95% documented in this study (Al-Aloul et al., 2004; O'Carroll et al.,
2004). The previous studies involved both antibiotic-resistant and susceptible strains of
P. aeruginosa, and neither study reached statistical significance due to the small number
of patients meeting their inclusion criteria, similar to the limitations of this study.
With the current rate of decline, patients in the dominant clone would reach
severe lung disease status (FEV1 < 40%) and qualify for lung transplantation (FEV1 <
30%) in less than 10 years (Belkin et al., 2006). To contrast, the median FEV1 for a 30
year old patient with CF is 60% (Patient Registry 2008 Annual Report, 2009), compared
to the median FEV1 of 51% (mean = 59%) in our dominant clone population with an
estimated age of 18 years (mean age at time of MRPA diagnosis = 14.22 years, mean
length of follow-up = 3.58 years) at the conclusion of the study. Considering that the
expected lifespan of a patient with CF was 37.4 years in 2008, it can easily be
hypothesized that infection with the dominant MRPA clone will ultimately be associated
with decreased life expectancy. Early studies of lung function concluded that patients
with an FEV1 value < 30% had a 50% chance of dying within two years (Corey et al.,
1997; Kerem et al., 1992).
From this data, it is reasonable to conclude that the dominant MRPA clone does
contribute to increased patient morbidity in terms of lung function and nutritional status
in the long-term (mean = 3.07 years post-MRPA infection diagnosis). The additional
hospitalization time experienced by patients in the dominant clone is also clinically
relevant. In the dominant clone group, 25 patients (78%) spent more than 10 days per
year in the hospital post-MRPA infection compared with 22 patients (56%) in the non-
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dominant clone group. A much higher hospitalization rate was also observed in the 10
patients who died (average of 94 days per year).
Chronological Evaluation of MRPA Diagnosis and Hospitalization
The clustering of diagnosis of MRPA infection in patients with CF was evident in
Figure 8. Groups of patients with CF infected with the dominant MRPA clone were
present from 2004-2006 with an additional cluster in mid-2008. Beyond 2007, the
majority of new MRPA infections were members of the non-dominant clone group.
While the rate of infection with the dominant clone appeared to be declining, the
continued incidence of new cases is further proof that a common source or mode of
transmission is present at the care center.
The chronological grouping recognized in MRPA infection diagnosis was further
confirmed by the evaluation of recent hospitalization episodes prior to MRPA diagnosis
in Figure 9. The clusters of dominant MRPA clone acquisition could be due to a shared
encounter with a patient previously infected with the dominant clone. It is difficult to
determine how the clone may be spread, but due to the significance of recent
hospitalization and the noticeable difference in hospitalization rates prior to MRPA
infection, nosocomial transmission of the dominant MRPA clone is suspected. When
comparing overlap of hospitalization in the non-dominant MRPA clone group, far fewer
patients had potential inpatient exposure to patients in the dominant MRPA clone group
or patients with undiagnosed MRPA.
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Significance of the Results
While no complete model comparing the dominant and non-dominant MRPA
clonal groups proved statistically significant by logistic regression or MANOVA, the
practical significance of the findings is useful and consistent with results of similar
studies. The lack of significance of demographic characteristics (gender, age at time of
CF diagnosis, and mother’s educational level) as risk factors for acquisition of a
particular clone can help narrow the variables that should be monitored. CFTR genotype,
and in turn phenotype, did not predict susceptibility to infection with the dominant
MRPA clone. Likewise, the data suggests that the patient’s BMI, FEV1, tobramycin use,
and culture results did not contribute to infection with the dominant clone. The most
clinically significant finding is the clustering of hospitalization with patients infected
with the dominant clone. With recent hospitalization as a statistically significant risk
factor for acquisition of the dominant clone and increased hospitalization rates in the year
prior to MRPA infection, the results do not rule out the possibility of a common source of
infection within the hospital. Significant overlap in hospitalization episodes between
patients infected with the dominant MRPA clone and patients who became infected with
the same clone a short time later further supports this theory.
The Hopital Erasme CF clinic in Brussels, Belgium was implicated as a common
source of P. aeruginosa infection in one study (Kersulyte et al., 1995), but inpatient
hospital stays were also documented as a risk factor for infection with the epidemic P.
aeruginosa clone. Inpatient encounters within two years of infection and overlapping
hospital stays were implicated in two studies as the reason for emergence of a dominant
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clone in patients with CF (Denton et al., 2002; Jones et al., 2001). Other studies went on
to document the presence of epidemic strains in environmental samples collected in the
clinic and hospital such as the water, sinks, creams, and counters (Bosshammer et al.,
1995; Festini et al., 2007). Further research into the Liverpool epidemic strain of P.
aeruginosa identified no clear environmental source of infection and determined that
airborne dissemination was the most likely culprit in patient-to-patient transmission
(Panagea, Winstanley, Walshaw, Ledson, & Hart, 2005).
The results confirm prior findings of increased virulence of an epidemic strain as
documented in the Liverpool, Sheffield, and Australian epidemic strains (Al-Aloul et al.,
2004; Edenborough et al., 2004; O'Carroll et al., 2004). Further investigation regarding
hospitalization also suggests a difference may exist in terms of transmissibility. Patients
infected with a non-dominant clone spent a substantial amount of time in the hospital
post-MRPA infection diagnosis, but no extensive outbreaks of other clones have been
discovered. The proliferation of the dominant clone during a period of several years
speaks to the potential increased transmissibility of this epidemic strain in this particular
patient care environment. Previous analysis of two epidemic P. aeruginosa strains in the
Australian CF clinics also found increased transmissibility, and additional studies
evaluating phenotypic characteristics have suggested that protease activity may play a
role in the increased infectivity of the strains (Tingpej et al., 2007). Subsequently, a
recent microarray analysis of the Australian Epidemic Strain-2 indicated that differential
gene expression in P. aeruginosa may increase transmissibility (Manos et al., 2009).
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Limitations
The largest limitation of the study is the sample size. This study was restricted to
patients with CF at one CF Center, and inclusion criteria required a confirmed diagnosis
of MRPA and prior consent to participate in the Port CF database. The small sample size
resulted in potentially insufficient statistical power and increased risk of a Type II error.
A significant relationship was realized between infection with the dominant clone and
recent hospitalization, but it is plausible that additional risk factors could exist. Similarly,
the low statistical power due to small sample size contributed to the inability of the study
to identify statistically significant differences in patient outcome. While clinically
significant differences were realized in terms of nutritional status and lung function, a
much larger sample size was necessary to reach statistical significance. For instance, a
published study regarding changes in lung function stated that for differences of 5% in
FEV1 rate of change a sample size of > 250 patients per group was necessary (Corey,
2007). As proof of that concept, an extensive study, comparing lung function of patients
with CF chronically infected with MRSA compared to those who are not, using data from
the national patient registry found that a -0.62% difference in rate of decline of FEV1 was
statistically significant (p < 0.001) (Dasenbrook, Merlo, Diener-West, Lechtzin, & Boyle,
2008). For comparison to this current study of 71 patients, the MRSA study included over
17,000 patients, of which 1732 patients were included in the MRSA infected group.
Further limiting the study was the inclusion of only one CF center. Because
consent for Port CF was required for a patient’s inclusion in the study and consent was
only obtained for this CF care center, it was not possible to obtain data from other
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centers. Therefore, it remains feasible that this dominant clone could be a geographic
anomaly specific to the TCH CF Care Center. Without molecular typing data from
patients across the country and access to clinical data for those patients, it is impossible to
determine whether the identification of this clone is a widespread problem or a single
instance of an endemic strain in one institution.
Finally, the minimal amount of information regarding details of hospitalization
episodes available in Port CF was a limitation to further analysis. Port CF simply
documents the dates and length of each encounter along with routine clinical data such as
lung function, nutritional status, medication regimen, and microbiology results along with
demographic information. Specific data regarding inpatient episodes such as which
practitioners were seen, timing and frequency of procedures performed, and even hospital
room number were not available. By obtaining access to this type of detailed information,
more specific studies could be designed to determine the potential sources of
transmission.
Implications for Clinical Practice
The significant relationship between recent hospitalization and acquisition of the
dominant MRPA clone is relevant to clinical practice for patients with CF. While patients
are expected to become chronically colonized with P. aeruginosa at some point during
the course of the disease, delaying the infection as well as preventing the acquisition of
multiply-resistant strains is of great importance to patient prognosis. The findings of this
study point to inpatient stays as a potential source of transmission of the endemic strain,
and a careful review of infection control processes is warranted. In addition, the results
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highlight the potential for increased transmissibility of the dominant MRPA clone, which
further reinforces the need for rigorous infection control standards. The CF Foundation
has issued many recommendations regarding infection control practices specific to clinics
and hospitals that care for patients with CF, but the extent to which those
recommendations are adhered can vary between and within care centers (Saiman &
Siegel, 2003). Following the confirmation of the existence of the dominant MRPA clone
group in 2006, TCH has undergone multiple improvements to the infection control
practices in the areas of the hospital that care for patients with CF. This appears to have
led to a decrease in the incidence of patients becoming infected with the dominant MRPA
clone as depicted in Figure 17. Discussion has also begun regarding implementation of
contact precautions for all patients during inpatient episodes.
Upon discovery of an endemic or epidemic strain within an institution, it would
be recommended to review infection control practices in all areas potentially caring for
patients with CF based on the results of this study. In addition, once the strain has been
identified, patients should be monitored closely for new infections, possibly by more
frequent respiratory cultures, following a recent hospitalization. Isolation precautions are
currently recommended for patients with MRPA, but review of how those procedures are
handled, in patients with CF at that particular institution, with hospital staff may be
prudent each time a patient currently infected with MRPA is admitted for inpatient
treatment. While TCH has staff dedicated to the CF Clinic and the Pulmonology floor,
education of interim personnel, such as float staff and fellows, as well as ancillary staff,
such as environmental or food service personnel, is vital. In addition, a methodical re-
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Figure 17. Infection Control Process Improvements in the Care of Patients with CF at
TCH.
Note: Multiple process improvements including the implementation of contact isolation upon admission
and renewed availability of proper equipment have coincided with a decrease in the number of MRPA
patients infected with the dominant MRPA clone.

education of each hospital section and specific personnel involved in the care of patients
with CF may be an additional resource in the prevention of transmission of an endemic or
epidemic strain of MRPA.
The results of this research further confirm the clinical utility of molecular typing
as a tool for epidemiological surveillance in cystic fibrosis. By identifying an endemic or
epidemic MRPA strain in the CF population, molecular typing enables care providers to
investigate possible sources of transmission and evaluate transmissibility of the identified
strain. In addition, the stratification of patients provided by molecular typing results
allows for the determination of differences in patient morbidity associated with infection
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with particular strains, which in turn provides information on potential virulence of the
strain.
Recommendations for Future Research
The most obvious recommendation for future studies is to expand the application
of molecular typing beyond one CF center. Inclusion of multiple CF centers in various
areas of the country would reveal if the dominant MRPA clone identified in this study is
a geographic anomaly specific to the TCH CF Care Center. Evaluating the MRPA
infection patterns at other institutions would determine if inpatient hospitalization plays a
role in acquisition of MRPA globally. In addition, the larger sample size would increase
the statistical power of the study. It is possible that factors that were not significant in this
study could become significant in an analysis of a much larger sample set.
In terms of the CF Care Center at Texas Children’s Hospital, new MRPA
infections should continue to be monitored by molecular typing to determine if the
isolates are members of the dominant MRPA clone group. If consent can be obtained
from the original CF care centers for the transplant consultation patients infected with
MRPA, then those patients should be added to the dataset in the future. Molecular typing
and comparison of clinical data for transplant patients will provide further information on
acquisition of the dominant clone, as well as determine if the dominant MRPA clone was
present in these patients prior to their first visit to Texas Children's Hospital. Inclusion of
transplant patients would also enable the use of variables related to lung transplant
evaluations and procedures as potential patient outcome parameters.
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In addition, patient outcome data for patients infected with MRPA should be
continually reviewed to track patient morbidity associated with infection with the
dominant MRPA clone. Additional years of patient outcome data for the two clonal
groups may yet produce statistically significant differences that were not evident in the
span of time during which this study was conducted. It is also worth noting that if
improved infection control processes continue to be effective in preventing the spread of
the dominant MRPA clone, then as patients originally infected by the endemic strain
either transfer to adult CF centers or die, the prevalence of MRPA infection in the TCH
CF Care Center should decrease and approach the national average.
An evaluation of the cost of molecular typing and the cost of treatment of patients
infected with the dominant MRPA clone is another avenue to consider. While molecular
typing costs are not charged to the individual patient, the cost to the hospital in terms of
financial support of molecular epidemiological surveillance and increased treatment of
the patients infected with the endemic MRPA strain would be useful information to both
health care providers and administrators.
Future studies should also focus on the overlap of hospitalization between
previously infected patients and new infections identified by molecular typing. While
increasing all infection control processes to curtail further spread of the organism is ideal,
determination of the original source of proliferation of the clone would provide valuable
information to CF centers worldwide. Studies designed to collect highly specific
information related to hospitalization episodes, such as each nurse, physician, or other
care provider that enters the room, every procedure performed including time and
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location, and even visitors to every patient, would enable centers to pinpoint the most
likely sources of infection.
Adding to the more detailed study of inpatient hospitalization parameters would
be an environmental sampling of the entire CF care center including the clinic and
dedicated areas of the hospital. While patients are routinely cared for in areas designated
for patients with CF, shared areas and equipment for physical therapy, patient transport,
and even meal delivery could harbor the endemic strain. A thorough microbiological
analysis of all sources of patient contact would be a difficult but medically valuable study
to undertake. Molecular typing would enable researchers to determine if strains isolated
from environmental samples were related to strains isolated from patients with CF.
Finally, it may prove beneficial to evaluate the degree of antibiotic resistance in
an endemic/epidemic strain population. While classification of a strain as multiplyresistant P. aeruginosa is based on resistance to all antibiotics in two of the three
recognized classes, incomplete resistance in the third class or which of the two classes for
which complete resistance was present could vary between clones as well as within
clonal groups. More thorough analysis of the different resistance patterns and how or if
they relate to molecular typing profiles may reveal additional data relevant to treatment
plans.
Summary and Conclusions
An endemic strain of multiply-resistant Pseudomonas aeruginosa was identified
in the patients of the CF Care Center at Texas Children’s Hospital. Molecular typing of
the patient isolates confirmed the presence of a dominant clone that persists in the
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institution through the conclusion of this study. Data concerning patient-related variables
prior to infection with MRPA, such as demographic information and factors related to the
time of MRPA acquisition and disease state just prior to MRPA infection diagnosis, were
compared between the dominant MRPA clone group and the non-dominant MRPA clone
group. Recent hospitalization, within 180 days of MRPA infection diagnosis, was found
to be a clinically and statistically significant factor in acquisition of the dominant MRPA
clone. Hospitalization rate in the year prior to MRPA infection was also higher for the
dominant clone group compared to the non-dominant clone group. The majority of
patients in the dominant clone group experienced a pre-MRPA diagnosis inpatient
episode concurrently with a patient previously diagnosed with the dominant MRPA
clone, and this extent of hospitalization overlap was not observed in the non-dominant
MRPA clone group. Patient outcome variables were compared between the two groups,
and clinically significant differences were noted in regard to nutritional status, lung
function, and hospitalization rate. The results suggest the potential for increased virulence
and transmissibility of the endemic MRPA strain.
The CF Care Center at Texas Children’s Hospital has had a higher than average
MRPA infection rate among patients for several years. The discovery of an endemic
strain in the center has led to improved infection control practices concerning both clinic
processes and inpatient protocols. A decrease in the number of patients infected with the
endemic strain was realized at the end of the data collection period for this study.
Continued monitoring by molecular typing will enable us to determine if this trend
continues, and further diligence in infection control based on the data provided by this
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study should allow for the elimination of common sources of multiply-resistant
Pseudomonas aeruginosa infections in patients with cystic fibrosis.
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